BioSpectrum India Edition June 2019

USP is the logical choice
for residual host cell DNA
Reference Standards

Residual host cell DNA must be minimized as much as possible during
production of therapeutic proteins. The removal or reduction of host cell
DNA is mandatory for biopharmaceuticals, requiring accurate and sensitive
tests to quantify such impurities and to meet guidelines established by
regulatory agencies.

USP will help you demonstrate removal of residual genomic DNA
throughout the lifecycle of your product by o ering:

• two highly characterized Reference Standards for residual host cell
DNA: CHO genomic DNA and E. coli genomic DNA.

• General Chapter <509> Residual DNA Testing that features:

– a publicly available, validated method to detect residual genomic DNA

– con irmed primer and probe sequences that provide lexibility in
choice of labeling reagents

USP o ers additional Performance Standards – broadly applicable
standards that are used to demonstrate and help ensure methods and
process performance throughout the product lifecycle of a biologic.

Reference Standards are associated with validated qPCR methods

Now available • CHO Genomic DNA RS (catalog #1130710)
• E. coli Genomic DNA RS (catalog #1231557)

For Reference Standards that you can trust, visit:

Biologics.usp.org/bsp

4 BIO CONTENT BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

The Indian Biopharma Industry with over 300 companies is
growing at 12 per cent growth against the pharma industry

growth which is passing through tough situation post-
GST, ban on manufacture, sale and distribution of over

340 fixed dose combination (FDC) drugs. For the
year 2018-19 the Biopharma Industry crossed Rs

22,124 crore over previous year’s revenue of
Rs 18,290 core with exports comprising of
Rs 14,423 crore in 2018-19 witnessing
growth over last year’s exports of

13,925 crore.

COVER
DESIGN BY:
DOMINIX STRATEGIC
DESIGN PVT. LTD.

COVERSTORY 17.........................................................................................................................................................

INDIAN BIOPHARMA INDUSTRY GROWING
AT 12% CROSSES ₹ 22,000 CRORE

21 22 23 24 25

SERUM INSTITUTE BIOCON LTD NOVO NORDISK GLAXOSMITHKLINE SANOFI
OF INDIA LTD INDIA PVT LTD PHARMACEUTICALS INDIA LTD
LTD

ADAR POONAWALLA DR KIRAN MELVIN D’SOUZA A VAIDHEESH N RAJARAM
CEO and MAZUMDAR-SHAW Managing Director Managing Director Managing Director
Managing Director Chairperson &
Managing Director 28 29 30
26
27 INTAS BIOLOGICAL BHARAT SERUMS
RELIANCE LIFE PHARMACEUTICALS E LTD AND VACCINES LTD
SCIENCES PVT LTD BHARAT BIOTECH LTD
INTERNATIONAL
LTD

KV SUBRAMANIAM DR KRISHNA ELLA BINISH CHUDGAR MAHIMA DATLA BHARAT V. DAFTARY
President Chairman and Managing Director Managing Director Chairman &
Managing Director Managing Director

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com BIO CONTENT 5

EXPERT SAYS TOPVIDEO Dr Sudhir Gupta,
Founder, Foundation
14 for Primary
Immunodeficiency
Indian vaccine industry - Diseases shares
more vibrant in coming years his expectations
Dr K V BALASUBRAMANIAM, from the industry
and government
Former Managing Director - Indian for treating
Immunologicals Ltd and Strategic Immunodeficiency
Management and Life Sciences Consultant Diseases.

31 31 32

PFIZER LTD INDIAN MACLEODS
IMMUNOLOGICALS PHARMACEUTICALS
LTD PVT LTD

S SRIDHAR DR K ANAND KUMAR RAJENDRA AGARWAL Scan the QR Code »
Managing Director Managing Director Managing Director
Stan Kachnowski,
32 33 33 Chair, HITLAB
talks about
LUPIN LTD ABBOTT INDIA LTD SHANTHA the growth of
BIOTECHNICS innovations taking
PVT LTD place in India.

VINITA D GUPTA AMBATI VENU DR MAHESH BHALGAT Scan the QR Code »
Chief Executive Officer Managing Director Executive Director
Saurav Kasera,
34 34 35 Co-Founder, Clirnet
elaborates on
ZYDUS CADILA BAXTER INDIA VENTRI the scenario of
HEALTHCARE LTD PVT LTD BIOLOGICAL pharmaceutical
PVT LTD marketing in India.

PANKAJ R PATEL RAVINDER DANG ANURADHA JITENDRA Scan the QR Code »
Chairman General Manager DESAI
Chairperon
35
REGULARS
SUN PHARMA
INDUSTRIES LTD BioEdit ........................................... 06
BioMail .......................................... 08
DILIP SHANGHVI Policy and Regulatory News........ 10
Managing Director Company News............................. 12
People News................................. 45
Supplier News............................... 47
BioEvent ........................................ 50

6 BIO EDIT BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

Big brother’s “watch”

It is a list that definitely no one wants to be in. But, final disposal of applications increased by 38 per cent.
India is among the 11 countries which have been Online filing of patents increased by 90 per cent.
put on the ‘priority watch list’ by the US Trade
Representatives recent Special 301 report. Remaining Most importantly, Indian government released a
out of this list is important for any trading partner new comprehensive IPR policy covering all forms of IP
country of the US since the inclusion indicates some in one document with a focus on awareness & building
inadequacies and problems regarding intellectual administrative capacity and aimed at promoting
property (IP) protection or denying market access to innovation. The new policy was immediately followed
innovators that rely on IP protection. by changing old rules of 2003 by introducing Indian
Patents Rules 2016 which included strict timelines to
India has been retained in the list “for lack of dispose of cases and streamline examination, resulting
sufficient measureable improvements to its IP in reduction in waiting period.
framework on long-standing and new challenges
that have negatively affected US right holders over Still, the US government seems to be not happy
the past year.” The report lists the long standing IP with the development. Its expectations reflect from
challenges that make it difficult for innovators to the October 2018 comments of the US government
receive and maintain patents in India. They include agency helping exporters on its website. It feels that
insufficient enforcement actions, copyright policies the measures are still not adequate as interpretation
that do not properly incentivize the creation and and application of law requires more clarity,
commercialization of content, and an outdated particularly related to compulsory licenses, pre grant
and insufficient trade secrets legal framework. opposition etc. It also feels that there is no protection
Additionally, the report states, India restricted the in the law against the unfair commercial use of test
transparency of information provided on state-issued data submitted to the government in the application
pharmaceutical manufacturing licenses, expanded for market approval of pharma products. Among its
the application of patentability exceptions to reject list of various inadequacies, those related to medicines
pharmaceutical patents. are the liberal price control and the Health Ministry
removing the requirement for companies to inform
On one hand the report admits that over the whether a drug is under patent or not while filing for
past year, India took steps to address intellectual manufacturing license.
property (IP) challenges and promote IP protection
and enforcement. On the other it says India’s overall Price control has proved to be a sensitive issue of
IP enforcement remains inadequate, and the lack of late and a bone of contention between regulator and
uniform progress across the country threatens to producers. One American company had even sought
undercut the positive steps that certain states have permission to withdraw its stents after the government
taken. It adds that in pharma sector the country controlled the stent prices. It is important for the US
continues to lack an effective system for protecting trade authorities to understand here that in any country
against the unfair commercial use and unauthorised with poor people the government needs to ensure that
disclosures of undisclosed tests or other data generated they get medicines at affordable prices. As a result
to get marketing approval. There are several such the government has to do a tight rope balance walk
negative comments. between pricing and IPR protection. On the other hand
the government should also effectively communicate
India has been taking various measures to overcome its steps taken in the direction of more effective IPR
the challenges, which has been showing some positive protection. Getting excluded from the ‘big brother’s’
results. A very important step has been to increase priority watch list should be a priority.
Patent examiners from 200 to 458. As a result of
this and other measures, examinations increased by Milind Kokje
72 per cent, grant of patents grew by 55 per cent and Chief Editor

[email protected]



8 BIO MAIL BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

Vol 17; Issue 05; May 2019 Acknowledgements

Acknowledgements I am so grateful to BioSpectrum
India for covering my startup venture
Swissnex India is thankful to CloudKrate in the magazine. I
BioSpectrum India for the great article received a good business opportunity
covering the Indo-Swiss Healthtech thereafter.
Conclave 2019.
- Shambhavi Naik, Bengaluru
- Yashaswini Kumar, Bengaluru
Agenda in need
Regulatory input
Although the Indian pharma industry
It is great to know that the has undergone a fast pace of change,
government is doing the much appropriate course corrections and
needed work to make things easy suitable policy interventions are
for the innovators and scientists necessary for sustenance of future
by conducting regular workshops. growth.
Innovation is definitely driving growth
and development across the globe. - Kaushik Banerjee, Ahmedabad

- Bianca N, Mumbai

Vol 17; Issue 05; May 2019 MM Activ Sci-Tech Communications

Publisher & Managing Editor: South Region New Delhi INTERNATIONAL
Ravindra Boratkar Alok Srivastava Kalyani Sharma
National Business Head- Media Coordinator Singapore
Editorial: Ad Sales & Marketing 103-104, Rohit House 3, MM Activ Singapore Pte. Ltd.
Chief Editor: Milind Kokje ‘NITON, Block ‘C’, I Floor, No.11/6, Tolstoy Marg, Connaught Place, Saradha Mani
[email protected] Palace Road, Bangalore-560 052 New Delhi - 110 001 Manager Admin &
Mobile: +91-9845128747 Tel. No: +91 11 4354 2737 Sales Support
Advisor - Content: Vijay Thombre Tel.: +91-80-41131912/13 [email protected] #08-08, High Street Centre,
[email protected] 1 North Bridge Road,
General Manager Content Creation Singapore - 179094
and Coordination: Narayan Kulkarni Mumbai Pune Tel: +65-63369142
Content Team: Ankit Kankar Fax:+65-63369145
Bengaluru: Dr Manbeena Chawla Manager- Product & Ankit Kankar [email protected]
New Delhi: Kalyani Sharma Manager- Product &
Mumbai: Prapti Shah Marketing Communication Marketing Communication USA
Pune: Dr Sonali Wankhade 156, Kaliandas Udyog Bhavan, Ashirwad, 36/A/2, S.No. 270, Pallod Media Representative:
Singapore: Hithaishi C. Bhaskar Babasaheb Woralikar Marg, Farms, Baner Road, Pune- 411045 Christen Pickens
Mumbai - 400 025 Mobile: +91-9579069369 Senior Connections Planner
Social Media Editor: Ankit Kankar Mobile: +91-9579069369 [email protected] Havas Media
[email protected] [email protected] 200 Hudson,
New York, USA, 10013
CFO & Special Correspondent: Nagpur Tel: +1 646 5875000
Manasee Kurlekar Manisha Boratkar [email protected]
402, Govind Apartments, Shankar Nagar Square,
Production & Design: Nagpur - 440 010. Tel. +91-712-2555 249 Europe
MM Activ Sci-Tech Communications Media Representative:
Anil Walunj Printed and published by Sandup Sherpa
Ravindra Boratkar on behalf of MM Activ Sci-Tech Communications Pvt Ltd Associate Digital Investment
Product & Marketing Havas Media
Ankit Kankar Printed at Spectrum Offset, D 2/4 Satyam Estate, Behind CDSS, Tel: +1347-482-0278
[email protected] Pandurang Colony, Erandwane, Pune - 411004. Tel : +91 20 2543 6556 [email protected]
TIN No: 09565712431
Content Creation and Published from Ashirwad, 36/A/2, S.No. 270, Pallod Farms,
Coordination: Near Bank of Baroda, Baner Road, Pune- 411045.Tel. No: +91 20 2729 1769
Dr Manbeena Chawla Website: www.biospectrumindia.com
[email protected]

Circulation, Subscription and
Media Enquiry:
Asmita Thakar
[email protected]



10 POLICY AND REGULATORY NEWS BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

AYUSH, CSIR to promote
traditional medicines

ICMR introduces A Memorandum of Understanding endeavor to pursue: R&D covering
Malaria Elimination (MOU) has been signed between fundamental research; AYUSH
Research Alliance the Ministry of AYUSH and specific diagnostic tools; linking
Council of Scientific and microbiome, gene expression
Indian Council of Medical Industrial Research (CSIR), and prakriti; multi-ingredient
Research has established ‘Malaria New Delhi for cooperation herbal formulations, including
Elimination Research Alliance- in research and education in their standardization; exploring
India (MERA-India)’ which is areas of traditional systems of modern scientific methods for
a conglomeration of partners medicine and its integration with integration with traditional Indian
working on malaria control. The modern science. Under the MoU, Systems of Medicine (ISM);
principal activity of the Alliance is both organizations shall jointly linking disease signatures; etc.
to prioritize, plan, conduct, scale
up and translate relevant research Cabinet approves MoU
in a coordinated and combinatorial between India, Bolivia
way in order to have a tangible
impact of this research on the The Union Cabinet has given ex-post facto approval to the Memorandum
population at risk for malaria. of Understanding between India and Bolivia in the Field of Traditional
The purpose of MERA India is to Systems of Medicine and
identify, articulate, prioritize and Homoeopathy. The MoU
respond to the research needs of was signed in Bolivia in
the country to eliminate malaria March, 2019. The MoU
from India by 2030. will provide a framework
for cooperation, and will
Health ministry be mutually beneficial
calls for dengue between the two countries
corners for promotion of traditional
systems of medicine and
The health ministry has asked homoeopathy. It will lead to
all centre-run hospitals to set promotion and propagation
up ‘dengue corners’, dedicated of Traditional Systems of Medicine and Homoeopathy in Bolivia, and
areas to provide treatment will boost the importance of AYUSH (Ayurveda, Yoga, Unani, Siddha and
to dengue patients, as part Homoeopathy) systems of Medicine in Bolivia.
of the National Vector Borne
Disease Control Programme IPC to facilitate regulatory process
(NVBDCP) guidelines. The for biosimilars, herbal drugs
‘Dengue Corners’ will have
designated staff that will cater Council of Scientific and Industrial between CSIR-CCMB and
to dengue patients. The aim Research’s constituent laboratory,
of setting up these dengue the Centre for Cellular and the IPC is the development of
corners is to provide seamless Molecular Biology (CSIR-CCMB),
and efficient healthcare service Hyderabad, and the Indian biopharmaceutical reference
to the patients during surge Pharmacopeia Commission (IPC),
in dengue incidence. These Ghaziabad, have joined hands to standards and impurities therein,
instructions are part of the facilitate the regulatory process
guildelines of the NVBDCP. for biosimilars and herbal drugs. development of monographs for
The scope of the memorandum
of understanding (MoU) signed important Monoclonal Antibodies

and identification of herbal drugs

based on DNA Barcode analysis.

This collaborative project will be

executed at par with pharmacopeia

standards of other countries.

Millipore Express® PHF Hydrophilic Filters

Sterilizing-grade PES filters for fast, efficient and
economical buffer filtration

• Faster flow rates than most
sterilizing- grade filters, reducing
process footprint

• Multiple steam-in-place or autoclave
sterilization cycles

• Single-use, gamma ready formats
• Broad chemical compatibility, high

and low pH 1–14
• Fully scalable product offering

For more details please contact
[email protected]

Merck, the vibrant M, Millipore, NatriFlo are trademarks of
Merck KGaA, Darmstadt, Germany or its affiliates.
All other trademarks are the property of their respective owners.
Detailed information on trademarks is available via publicly accessible resources.
© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates.
All Rights Reserved

The life science business of Merck operates as
MilliporeSigma in the U.S. and Canada.

12 COMPANY NEWS BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

SIFI, Zydus to bring innovative Merck Limited
intraocular lenses in India changes name to
Procter & Gamble
SIFI, the Italian leader in the Health Limited
development of therapeutic solutions to
treat ophthalmic disorders and global Following P&G’s global acquisition
pharmaceutical major, Zydus Cadila, of the consumer health business
have tied up to market innovative IOLs of Merck KGaA, Darmstadt, the
(Intraocular lenses) and surgical products Company has received approval
developed in Italy and licensed in India by from the Registrar of Companies,
SIFI. SIFI’s innovative IOLs (Intraocular Mumbai, Maharashtra for change
lenses) have been approved by the Central of name from Merck Limited to
Drugs Standards Control Organization Procter & Gamble Health Limited
(Directorate General of Health Services) effective May 6, 2019. Procter &
and Ministry of Health & Family Welfare Gamble Health Limited will be
(Medical Device and Diagnostic Division). a part of P&G’s Personal Health
Care International Business Unit
Glenmark launches novel led by Uta Kemmerich-Keil (Vice
anti-diabetes drug in India President, Personal Health Care
International) which encompasses
Glenmark Pharmaceuticals Ltd., a research-led global integrated the health care businesses in
pharmaceutical company, has announced the launch of its novel, patent Europe, Latin America, and Asia/
protected and globally-researched sodium glucose co-transporter-2 IMEA (India, Middle East and
(SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India. Africa).
The drug is indicated in the treatment of type-2 diabetes mellitus in
adults. Glenmark is the first company in the world to launch the novel Alembic forms
SGLT2 inhibitor Remogliflozin and India is the first country to get access JV to sell
to this innovative drug. Glenmark will commercialize Remogliflozin in products in
India under the brand names “Remo” and “Remozen”. Chinese market

Lupin to market Osteoarthritis Alembic has entered into a Joint
product by Aptissen in Canada
Venture Agreement (JVA) dated

7th May, 2019 with SPH SINE

in Canada. This includes Pharmaceutical Laboratories
immediate rights to distribute
Synolis VA for the treatment Co Ltd, China (‘SPH Sine’) &
of Osteoarthritis. Based on
Statistics Canada, Osteoarthritis Adia (Shanghai) Pharma Co Ltd,
affects more than 10 per cent
of Canadians aged 15 or older. China (‘Adia’) to promote and
Synolis VA (Visco-Antalgic)
is the intra-articular injection sell pharmaceutical products for
product for osteoarthritis
with a unique combination the Chinese market. Initially this
of Hyaluronic Acid and high
concentration of Sorbitol. JV will commercialize products
Synolis VA 40/80 is already
approved by Health Canada manufactured by Alembic
and an additional strength is
currently under review. Pharmaceuticals Limited.

Lupin Limited (Lupin) and Subsequently the JV plans to set
Aptissen S.A. (Aptissen)
have entered into a definitive up a manufacturing facility in
distribution agreement under
which Aptissen has granted China. The JV will commercialize
Lupin the exclusive rights to
market, distribute and sell products in the Chinese market
the current Aptissen products
which has an increasing demand

for generic drugs. SPH Sine,

Alembic & Adia shall hold 51, 44 &

5 per cent equity in the JVA.



14 EXPERT SAYS BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

Indian vaccine industry -
more vibrant in coming years

« account for significant value of Rs 2000 crore. With
sales revenues from institutions pegged at Rs 800
Dr K V crore, the domestic human vaccine industry generates
BALASUBRAMANIAM, revenues of about Rs 2800 crore.
Former Managing
Director - Indian Not to be left behind, the animal vaccine segment of
Immunologicals Ltd and this industry also supports large livestock vaccination
Strategic Management programmes of the State Governments, by supplying
and Life Sciences about 0.5 billion doses of 7 important animal vaccines.
Consultant India is home to a large livestock population and its
significant agrarian economy is still dependent on
With a + 7 per cent economic growth, India livestock for much of stable, rural income. The animal
now leads the world ranking on a major vaccine segment generates sales revenues of about Rs
economic indicator viz. economic growth. 800 crore.
However, India has to still emerge out of debilitating
poverty which affects a large number of its people and Thus collectively, the Indian vaccine industry
also significantly improve the quality of life of most supplies about 1.5 billion doses, of both human
of its people. Pulling the vast number of Indians out and animal vaccines, of value Rs 3600 crore to the
of poverty calls not just for higher economic growth domestic market. Adding exports of Rs 3100 crore, the
with equity and equality, but also access to good industry generates sales revenues of Rs 6700 crore. It
healthcare, improved sanitation and better quality of is also growing at a healthy rate of 10 per cent p.a.
the environment.
This is no small achievement considering that
On the healthcare side, India accounts for a manufacture of vaccines requires the highest level
major portion of the world population suffering from of life science technologies to be deployed, an
communicable and non-communicable diseases. extensive range of testing for safety and efficacy; and
Much of modern health care is neither accessible nor achieving low costs through high scales of operations.
affordable by most Indians. Even where available, Several Indian vaccine companies are World
there are several health delivery issues to be dealt Health Organization (WHO) pre-qualified for their
with. The Indian vaccine industry works in this manufacturing sites. They are also partnering with
setting, which makes affordability and accessibility
paramount for preventive health care. international agencies in the development of new
vaccines for diseases affecting the developing and
The Indian Vaccine Industry least developed countries. No wonder that Indian
vaccine industry stands counted as a prominent
The importance of the Indian vaccine industry can be group in the global vaccine industry with its Unique
gauged by the fact that it supports a massive Universal Selling Proposition (USP) of quality, affordability and
immunization programme of the Government of reliability.
India and preventive health care programmes of State
Governments, by supplying about 1 billion doses of Immunization in India
12 important human vaccines. In addition, thanks to
its ability to make high quality vaccines at affordable However, ironically India has still a long way to go
prices, the Industry exports over 0.7 billion doses to achieve total immunization of its children and in
of human vaccines largely to the Global Alliance for protecting them against major diseases. Polio
Vaccines and Immunization (GAVI) supported United has only recently been eradicated in India
Nations Childrens’ Education Fund (UNICEF)’s and among the last few countries to do
Global immunization programme in the developing so. Some recent field incidents
and least developing countries. concerning polio did cause some
scare but fortunately, a
A number of other vaccines are sold in the private
trade, which though do not add up in terms of volumes,

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com EXPERT SAYS 15

good surveillance mechanism and pre-emptive action Top 10 human vaccine companies
addressed the issue. Notwithstanding this, India still (in the descending order of sales
has several adverse field events, not so much due to the in domestic market)
quality of the vaccines, but due to poor immunization
practices by an over-burdened immunization ● Glaxo Smith Kline Ltd
workforce dependent on an ageing and weak health ● Sanofi India Ltd
infrastructure for immunization. ● Serum Institute of India
● Biological E Ltd
The present immunization coverage rate in India ● Bharat Biotech Intl. Ltd
stands at 89 per cent, however with a wide disparity ● MSD India
in coverage since 37 per cent of the districts have ● Indian Immunologicals Ltd
immunization less than 80%. This is much lower ● Panacea Ltd
when compared to other developing countries such ● Zydus Cadila Ltd
as Srilanka or Thailand which have 99 per cent ● Wockhardt Ltd
coverage. The number of diseases covered in primary
immunization in India was until a few years ago only 7 more important than Hib to be addressed?
(for BCG, Polio, DTP, Hep B and Hib) and this has now Immunization coverage in India is also lower among
increased to 10 (Japanese Encephalitis, Rotavirus and
Rubella added) thanks to the Indradhanush initiative developing countries due to low public awareness
of the Government. Compared to over 14 diseases on the value of vaccination and lack of wholehearted
(plus Influenza, Varicella, Rubella, Pneumonia) involvement of people in immunization drives
covered by the developed countries for immunization undertaken by the Government. Low appreciation of
of their children, means that disease coverage in India the value of vaccines is particularly acute in the animal
has to still improve. vaccines market. To compound this, periodic adverse
events affects trust that people repose in vaccines.
Therefore, while it may feel good to have a vibrant Effective communication to overcome this, both by
vaccine industry earning laurels at the global level, the industry and the Government, is inadequate.
the vibrancy must be matched by serious concern
about the state of immunization and must result in In India’s federal structure the States carry out
positive efforts by the Government to improve both immunization, while funding of immunization
immunization and disease coverage. programmes is largely met by the Central Govt. For
a developing country like India with a multitude of
Challenges demands on Government for health interventions, this
imposes limitations on the budgets for immunization.
The Indian vaccine industry is faced This also directly affects uptake of vaccines and in
achieving effectiveness of immunization.
with several macro and micro
Vaccines must be stored and transported at low
level challenges, which are briefly temperatures. In a tropical country like India, with
poor transport networks in some major regions, this is
described below. a serious challenge. It is only of late that much emphasis
is being placed on creating a proper transport network
Indiasuffersfrominadequatedata and vaccine storage infrastructure in the country. It
will be a while before this significantly improves. Till
on disease burden in order to take then, the cost of logistics in the vaccine business will
continue to be challenging.
prudent decisions about diseases
Development of new vaccines is largely left to
to be covered in its immunization the private sector. The steps taken by the various
government agencies to fund new vaccine development
programmes. As a result, have not had much material effect in terms of bringing
to the market new vaccines relevant to our country.
the Government is Sustained efforts in the development of vaccines even
for diseases like Japanese encephalitis, Chikungunya
often criticized that or Swine fever, which periodically plague some parts of
the country, are not high priority for the private sector
decisions on vaccines as they do not pay off commercially. Besides, the eco
system in biotechnology is not mature to support new
to be included in

the immunization

programmes are

dictated by the industry and

are not considered decisions by

immunization experts. For example,

why would Hib take priority

over rubella in the immunization

programme considering that rubella

is a serious disease particularly

causing congenital rubella syndrome

(CRS) in infants and is considered

16 EXPERT SAYS BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

Top 10 animal vaccine companies commercial payoff. This is also a challenge to keep the
(in the descending order of sales present cost competitiveness alive in the face of higher
in the domestic market) regulatory demands.

● Indian Immunologicals Ltd Opportunities
● Brilliant Biopharma Pvt Ltd
● Venkateshwara Hatcheries Group It is said that when the going gets tough, the tough
● Hester Biosciences Ltd get going! The Indian vaccine industry has, thanks to
● MSD India its international exposure, technology development
● Zoetis Ltd partnerships and access to a large domestic market,
● Indovax Ltd been able to progressively develop capabilities in
● Biovet Ltd applied research and vaccine development. As a result,
● Boehringer Ingelheim Ltd it is now well placed to harness new opportunities
● Biomed Ltd in the emerging vaccine space. In the following
paragraphs, a few important challenges are described.
basic research which is direly needed for new vaccine
development. It is expected that a large private market will emerge
for vaccines in India. The Rs 2000 crore private domestic
For vaccines not covered by the Government, human vaccines market today accounts for only 7 per
spending is by private savings of citizens. However, the cent of the market by volume but 70 per cent of the
vaccines sold in the private market (for Rabies, Typhoid, market by value. Both on account of the growth in the
Influenza, Pneumonia, Hepatitis A, Chicken pox, HPV economy and due to targeted Government programmes
and combination vaccines) are largely from the stable to reduce rural poverty and improve standard of living, it
of multi-national companies. They are expensive and is expected that the vaccine industry will benefit in good
only serve the more affluent people in the metros and measure. The opportunity will be for vaccines which are
major non-metro cities. It is ironical that although not in the Universal Immunization Programme (UIP)
the vaccines sold by multinational companies are basket, viz. Rabies, Typhoid, Influenza, Pneumonia,
solely to the private market and not to the government Hepatitis A, Chicken pox, Human papilloma virus and
programmes, they yet account for nearly 50% of the combination vaccines, and sold in the private market.
sales revenues in the domestic market. Therefore, there More indigenous market offerings by domestic players
is need to pursue the objective of making vaccines can be expected. However, it must be stated that
affordable to the larger population. keeping these vaccines affordable can help improve
market penetration.
The regulatory environment in India for
biopharmaceuticals in general and vaccines in particular, The opportunities for exports will continue,
has seen significant changes in the recent past. This especially to the GAVI/UNICEF procurement
makes regulatory approvals for vaccines arduous, time programmes for immunization in the least developed
consuming and costly. As a result, interest of the private countries. More Indian players are expected to meet
sector for development of vaccines for orphan diseases the stringent WHO Pre-qualification requirements
remains very muted since there is no commensurate for even more number of vaccines. This would help
increase the revenues and profitability of the industry.

On the technology side, since newer vaccines are
based more on recombinant DNA technologies, it can
be expected that companies will focus more on building
such technology capabilities. This can have spin offs
in terms of development of other bio-therapeutic
products. This will be a logical extension to the human
therapeutic market for the Indian vaccine industry.

Summary

In summary, it can be stated that while the Indian
vaccine industry is beset with numerous challenges-
often faced by growing industries, there are significant
opportunities for growth with more depth in the
domestic market, more breadth in product offerings
and from progressively higher technology capabilities.
The industry can thus be expected to be even more
vibrant in the coming years.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 17

INDIAN BIOPHARMA
INDUSTRY GROWING AT

12% CROSSES
₹ 22,000 CRORE

The Indian Biopharma Industry with over 300 According to AIOCD Pharmasofttech AWACS Pvt.
300 companies is growing at 12 per cent Ltd, there are over 200 companies in blood related
growth against the pharma industry growth products. Pfizer is leading the market in the country
which is passing through tough situation with sales of Rs 150 crore in 2018-19. Abbott India is
post-GST, ban on manufacture, sale and leading the hormones market in India with Rs 349
distribution of over 340 fixed dose combination (FDC) crore in 2018-19. In the hormones space too there are
drugs. For the year 2018-19 the Biopharma Industry about 200 companies in the business.
crossed Rs 22,124 crore over previous year’s revenue
of Rs 18,290 core with exports comprising of Rs 14,423 Only in insulin and vaccines space the number
crore in 2018-19 witnessing growth over last year’s of companies are less than 20 and 40 respectively.
exports of 13,925 crore. GlaxoSmithKline Pharmaceuticals Ltd. is leading
the vaccines business in the country (out of pocket)
Indian Biopharma industry, comprising hormones, with sales of Rs 662 core. Novo Nordisk India Pvt Ltd
insulin, blood products and vaccines also imported continues to lead the insulin market with
biopharma products worth Rs 5500 core in 2018-19 as Rs 1351 crore. In all these biological
against previous year’s imports of Rs 5039 crore. segments the domestic market
is being led by multinational
Serum Institute of India Ltd continues to lead the companies. However Indian
Indian biopharmaceutical industry with a revenue of companies do have some
Rs 4984 crore followed by Biocon (Rs 3946 crore) and presence but still they
Novo Nordisk with Rs 1352 crore. Top 3 biopharma need to do a lot to
companies contribute to 46 per cent of the total come at par with
biopharma industry of Rs 22,145 crore. And Top 20 the multinational
biopharma companies contribute to 89 per cent of companies.
the total biopharma industry.

Western region continues to dominate the
biopharma industry with contribution of 59 per cent
followed by Southern region with 36 per cent and
remaining 4 per cent coming from Northern region.

Indian biopharma companies exported Rs 8100
crore worth hormones and related products
during 2018-19 against Rs 7963 crore worth
of products in 2017-18. Vaccines
worth Rs 4453 crore were
exported in 2018-19.

18 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

SERUM INSTITUTE
OF INDIA LTD

RETAINS
No. 1 POSITION

Serum Institute of India Ltd continues to lead the Indian
biopharmaceutical industry with revenue of Rs 4984 crore followed
by Biocon (Rs 3946 crore) and Novo Nordisk with Rs 1352 crore.

BioSpectrum Top 20 BioPharma Companies 2019

Sr. Company Revenue Revenue % Category Location Region
No. in 2018-19 in 2017-18 Growth

1 Serum Institute of India Ltd 4984 3987 25 India Pune West

2 Biocon Ltd 3946 2890 37 India Bengaluru South

3 Novo Nordisk India Pvt Ltd 1352 1180 15 MNC Bengaluru South

4 Glaxosmithkline Pharmaceuticals Ltd 972 898 8 MNC Mumbai West

5 Sanofi India Ltd 948 842 13 MNC Mumbai West

6 Reliance Life Science Pvt Ltd 850 708 20 India Mumbai West

7 Bharat Biotech International Ltd 774 705 10 India Hyderabad South

8 Intas Pharmaceuticals Ltd 708 443 60 India Ahmedabad West

9 Biological E Ltd 672 504 33 India Telangana South

10 Bharat Serums & Vaccines Ltd 600 540 11 India Mumbai West

11 Pfizer Ltd 579 619 -7 MNC Mumbai West

12 Indian Immunologicals Ltd 538 460 17 India Hyderabad South

13 Macleods Pharmaceuticals Pvt Ltd 406 338 20 India Mumbai West

14 Lupin Ltd 381 345 10 India Mumbai West

15 Abbott India Ltd 371 288 29 MNC Mumbai West

16 Shantha Biotechnics Pvt Ltd 369 NA NA India Hyderabad South

17 Zydus Cadila Healthcare Ltd 362 340 7 India Ahmedabad West

18 Baxter India Pvt Ltd 300 250 20 India Gurugram North

19 Ventri Biological Pvt Ltd 250 230 9 India Pune West

20 Sun Pharma Industries Ltd 237 218 9 India Mumbai West

Top 3 biopharma Top 10 biopharma Top 20 biopharma

companies contribute companies contribute companies contribute

46%to of the total 71%to of the total 89%to of the total

biopharma industry biopharma industry biopharma industry

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 19

BioSpectrum Top 21-50 BioPharma Companies 2019

Sr. No. Company Revenue in 2018-19 Revenue in 2017-18 % Growth Category Location Region
21 Panacea Biotec Ltd 218 186 17 India New Delhi North
22 Wockhardt Ltd 197 221 -11 India Mumbai West
23 Emcure Pharmaceuticals Ltd/ Gennova Biopharmaceuticals Ltd 181 170 6 India West
24 Eli lilly and Company (India) Pvt Ltd 161 141 14 MNC Pune North
25 Fresenius Kabi India Pvt Ltd 145 138 5 MNC Gurugram West
26 Brilliant Bio Pharma Pvt Ltd 140 130 8 India South
27 Abbott healthcare Pvt Ltd 129 123 5 MNC Pune West
28 Hester Biosciences Ltd 128 120 7 India Hyderabad West
29 MSD Pharmaceuticals Pvt Ltd 96 166 -42 MNC West
30 Haffkine Bio-Pharmaceutical Corporation Ltd 85 195 -56 India Mumbai West
31 Bharat Immunologicals and Biologicals Corporation Ltd 84 35 140 India Ahmedabad North
32 Biovet Pvt Ltd 60 55 8 India South
33 Zuventus Healthcare Ltd 57 46 23 India Mumbai West
34 La renon Healthcare Pvt Ltd 55 57 -2 India Mumbai West
35 Mankind Pharmaceuticals Ltd 51 48 7 India Bulandshahr North
35 Indovax Pvt Ltd 51 48 7 India Bengaluru North
36 Micro Labs Ltd 48 56 -14 India Mumbai South
36 Dr. Reddys Laboratories Ltd 48 46 2 India Ahmedabad South
37 Samarth Life Sciences Pvt Ltd 35 28 25 India New Delhi West
38 Shreya Life Sciences Pvt Ltd 34 24 44 India Gurugram West
39 Paviour Pharmaceuticals Pvt Ltd 33 44 -25 India Bengaluru North
39 Ozone Pharmaceuticals Ltd 33 26 26 India Hyderabad North
40 Cipla Ltd 32 31 3 India Mumbai West
41 Greensignal Bio Pharma Pvt Ltd 30 28 7 India Mumbai South
42 Claris Lifesciences Ltd 25 29 -15 India New Delhi West
43 Wallace Pharmaceuticals Ltd 24 20 17 India New Delhi West
44 Alkem Laboratories Ltd 23 21 13 India Mumbai West
44 Rpg Life Sciences Ltd 23 13 70 India Chennai West
44 Juggat Pharma Ltd 23 21 6 India Ahmedabad South
45 Astrazeneca Pharma India Ltd 21 16 27 MNC South
45 Cadila Pharmaceuticals Ltd 21 14 44 India Goa West
46 Jagsonpal Pharmaceuticals Ltd 20 16 27 India Mumbai North
46 Corona Remedies Pvt Ltd 20 15 36 India Mumbai West
47 Ferring Pharmaceuticals Pvt Ltd 19 17 16 MNC Mysuru West
48 Boehringer Ingelheim India Pvt Ltd 18 26 -31 MNC Bengaluru West
49 Neon Laboratories Ltd 18 17 8 India Ahmedabad West
49 Mercury Health Care Pvt Ltd 17 15 11 India New Delhi West
50 Oaknet Healthcare Pvt Ltd 16 16 0 India Ahmedabad South
50 Raptakos Brett & Co. Ltd 16 15 10 India Mumbai West
Mumbai
Mumbai
Mumbai
Bengaluru
Mumbai

BIOSPECTRUM BIOPHARMA
SURVEY AND METHODOLOGY

BioSpectrum India, their achievements in the past the analysis are biologicals sales
a leading B2B financial years. and service figures. In several
media platform in cases, where revenue figures
Lifesciences space A detailed questionnaire were not available, estimates
since 2003 has re- (survey form) was sent to over 100 were arrived in discussion with
launched its ranking special companies in biologicals space to industry experts.
edition in June 2019 after gap of capture the needed information
2 years. In this survey we looked for the analysis. This was done For all the ranking purposes,
at only the Biopharma Industry during May 2019. Companies we have taken the biopharma
with companies specializing shared information with us to the business only into consideration.
in Biologics/ Recombinant extent it was possible by them. Wherever ‘Revenue is mentioned,
products/ mAbs/ Vaccines/ We have collected information it means, sales turnover from
Insulin. We highlighted the about listed companies from biopharma division. Therefore,
companies (both MNCs and stock exchange and financial revenue wherever mentioned
domestic players) based on agencies as well. is not necessarily the total sales
turnover of the company.
The revenues considered for

20 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

BioSpectrum Top 10 Indian Biopharma companies

Sr. Company Revenue Revenue % Location Region
No. in 2018-19 in 2017-18 Growth
Pune West
1 Serum Institute of India Ltd 4984 3987 25 Bengaluru South
3946 2890 37 Mumbai West
2 Biocon Ltd 850 708 20 Hyderabad South
774 705 10 Ahmedabad West
3 Reliance Life Science Pvt Ltd 708 443 60 Telangana South
672 504 33 Mumbai West
4 Bharat Biotech International Ltd 600 540 11 Hyderabad South
538 460 17 Mumbai West
5 Intas Pharmaceuticals Ltd 406 338 20 Mumbai West
381 345 10
6 Biological E Ltd

7 Bharat Serums & Vaccines Ltd

8 Indian Immunologicals Ltd

9 Macleods Pharmaceuticals Pvt Ltd

10 Lupin Ltd

Indian companies

contribute

78% of the

total biopharma

industry while

22%remaining

by the MNC firms.

BioSpectrum Top 10 MNC Biopharma companies

Sr. Company Revenue Revenue in % Location Region
No. in 2018-19 2017-18 Growth
Bengaluru South
1 Novo Nordisk India Pvt Ltd 1352 1180 15 Mumbai West
972 898 8 Mumbai West
2 Glaxosmithkline Pharmaceuticals Ltd 948 842 13 Mumbai West
579 619 -7 Mumbai West
3 Sanofi India Ltd 371 288 29 Gurugram North
161 141 14 West
4 Pfizer Ltd 145 138 5 Pune West
129 123 5 Mumbai West
5 Abbott India Ltd 96 166 -42 Mumbai South
21 16 27 Bengaluru
6 Eli Lilly and Company (India) Pvt Ltd

7 Fresenius Kabi India Pvt Ltd

8 Abbott Healthcare Pvt Ltd

9 MSD Pharmaceuticals Pvt Ltd

10 Astrazeneca Pharma India Ltd

Western region continues to dominate the biopharma industry with

59% 36%contribution of and remaining
followed by Southern region with

4% coming from Northern region.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 21

01

SERUM INSTITUTE OF INDIA LTD

REVENUE CONTINUES WORK
ON NEWER VACCINES
₹ 4984 crore
Pune based vaccine manufacturer Serum Institute of India
ADAR POONAWALLA (SII) recorded the highest amount of revenue in FY18-19 at
Rs 4984 crore exhibiting a growth of 25 per cent from the
CEO and Managing Director last fiscal’s revenue at Rs 3987 crore.
2018 saw the company announcing a strategic
partnership with the International AIDS Vaccine Initiative (IAVI) to
develop and manufacture affordable and accessible monoclonal
antibody products for HIV and other global health challenges.
In addition, SII also launched a nation-wide vaccination and
immunisation campaign called ‘Swasth Immunised India’ in
association with Network18 to spread awareness on the importance
and benefits of immunisation among the general populace.
As a latest development, the company has collaborated with US
headquartered Dyadic International to develop and manufacture up
to twelve antibodies and vaccines using Dyadic’s C1 gene expression
platform. This collaboration is focused on making biologic vaccines
and drugs accessible and more affordable to patients worldwide
while lowering the financial burden on the global healthcare system.
Founded in 1966, SII supplies around 30 different products
overseas majorly in the categories of bacterial vaccines,
polysaccharide conjugate vaccines, influenza vaccines, anti-sera, viral
vaccines, uro-oncology, recombinant products and combination
vaccines. On the other hand, around 60 products are supplied by
the company in India under bacterial, viral, combination vaccines,
recombinant products, gonadotrophins, and pharma products.
SII manufactures highly specialized lifesaving biologicals like
vaccines using cutting edge genetic and cell based technologies,
antisera and other medical specialties. The company is considered
the world’s largest vaccine manufacturer by the number of doses
produced and sold globally (more than 1.3 billion doses) which
includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis,
Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is
estimated that about 65 per cent of the children in the world receive
at least one vaccine manufactured by Serum Institute. Vaccines
manufactured by SII are accredited by the World Health Organization,
Geneva and are being used in around 170 countries across the globe
in their national immunization programmes.
SII made its first International acquisition by acquiring Bilthoven
Biologicals, a bioengineering and pharmaceutical company from
The Netherlands Government in 2012. The takeover ensures access to
technology and expertise for making the IPV (Injectable Polio Vaccine,
Salk), earlier possessed by only 3 other vaccine manufacturers.

22 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

02

BIOCON LTD

REVENUE SUSTAINING
GROWTH MOMENTUM
₹ 3946 crore
Bengaluru based Indian biopharmaceutical company
“FY18-19 was a landmark year for Biocon recorded a revenue of Rs 3946 crore during the
the Biologics business, which reported FY18-19 in the biologics, small molecules and branded
formulations space, showing a growth of 37 per cent from
a growth of 97 per cent, thus the previous financial year 2017-18 where the revenue
emerging as a key driver for Biocon’s count was Rs 2890 crore. The Biologics segment was the strongest
performing segment in FY18-19, reporting a stellar 97 per cent
incremental growth. Our three revenue growth at Rs 1,517 Crore. It has been a landmark year for the
strategic business segments Small biosimilars business with revenues doubling led by the launch of
Molecules, Biologics and Research Biocon’s key biosimilars in the U.S. and Europe and ramp up of sales
Services have reported a top-line of in the emerging markets. Inclusive of inter-segment transfers, the
over Rs 1,500 Crore each this fiscal. Biologics business crossed the $ 200 million revenue milestone in
Looking ahead in FY19-20, we expect FY18-19. The launch of Fulphila (biosimilar Pegfilgrastim) in the U.S.
by Biocon’s partner Mylan contributed significantly to the Biologics
to sustain the growth momentum segment’s performance in FY18-19. Mylan also launched Semglee
across our business segments led (biosimilar Insulin Glargine) and Ogivri (biosimilar Trastuzumab) in
by biosimilars. We expect to sustain Europe along with the in-licensed biosimilar Adalimumab, where
core EBITDA margins despite higher Biocon retains its economic interest. Significant growth in biosimilars
R&D investments to fuel our future sales was reported from emerging markets in LATAM, APAC and
MENA regions. The global development programs for biosimilar
growth.” Bevacizumab and Insulin Aspart are progressing well in Phase III
clinical studies.
DR KIRAN MAZUMDAR-SHAW In the novel biologics segment, a Phase 1b/2 trial in acute
graft-versus-host disease (aGVHD) with the company’s novel asset
Chairperson & Managing Director Itolizumab (EQ001) was initiated by its partner Equillium in the
FY18-19. In addition, Biocon launched Canhera, as the first biosimilar
Trastuzumab in UAE in 2018 to enable affordable access to this
therapy for breast cancer patients.
On the other hand, the Branded Formulations business, which
includes sales in India and UAE, was adversely impacted due to
headwinds in UAE. However, the business in India reported a strong
performance led by double-digit growth in Metabolics, Critical Care,
Immunotherapy and Market Access divisions.
Founded in 1978, Biocon has created a rich pipeline of novel and
biosimilar assets over the years primarily in the areas of oncology,
diabetes, immunology and autoimmunity. With more than 9000
employees Biocon has today emerged as the largest insulin producer
in Asia. It is also among the Top 3 biosimilars players globally in both
rh-Insulin and Insulin Glargine in terms of volume market share.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 23

03

NOVO NORDISK INDIA PVT LTD

REVENUE CONTINUING TO
CHANGING DIABETES
₹ 1352 crore
The Indian arm of Denmark headquartered company Novo
MELVIN D’SOUZA Nordisk saw a revenue generation of Rs 1352 crore in the last
financial year 2018-19 in the biologics space, as compared to Rs
Managing Director 1180 crore in the previous year FY17-18, exhibiting a growth of
approximately 15 per cent.
On the diabetes front, Novo Nordisk Education Foundation (NNEF)
and Novo Nordisk India launched a ‘1000-day Challenge’ programme
in November 2018 in New Delhi, along with leading healthcare
practitioners to address uncontrolled diabetes in India. In addition,
for the first time, real-time data on the state of diabetes care was
announced to be made available through an innovative “India Diabetes
Care Index”. Although Novo Nordisk insulins have been present in India
from 1935 marking more than 80 years of uninterrupted supply, the India
arm started operations in 1992 with its headquarters in Bengaluru. The
company has over 1,300 employees, and are the 5th largest and one of
the fastest growing pharmaceutical MNCs in India.

Novo Nordisk started its Global Service Center (GSC) in Bengaluru
in 2007. It is an integral part of Novo Nordisk A/S and was piloted as a
shared services team. Since then it has grown in scale and scope to over
1,700 talented colleagues today, catering to global operations of Novo
Nordisk, and spread across 12 different functions supporting the entire
pharma value chain. The GSC expects to hire up to 600 by 2020. The GSC
is anchored under the Executive Management in Denmark and has a
high degree of visibility across the globe, and significant impact on Novo
Nordisk’s overall performance.

For Novo Nordisk, India is one of the key countries where the
company has applied for advance pricing agreements (APAs) to create
certainty regarding tax payments. Novo Nordisk has APAs in place
covering intercompany transactions with the US, Canada, Japan, India
and China corresponding to more than 60 per cent of total sales.

Globally, the FY18-19 also saw Novo Nordisk making key
announcements such as a partnership with Abbott to provide integrated
digital solution to people with diabetes using insulin, and to make the
durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus
commercially available across key markets commencing in 2019.

With a global employee strength of 43202 spread across 80
countries, the company’s biological products are grouped under
four major categories- Diabetes, Obesity, Hemophilia and Hormone
Replacement Therapy. The maximum revenue generation is brought
about by the products in the diabetes (81 per cent) sector followed by
hemophilia (9 per cent), growth disorders (6 per cent) and obesity (3 per
cent).

24 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

REVENUE GLAXOSMITHKLINE 04
PHARMACEUTICALS LTD
₹ 972 crore
FOCUSING ON
A VAIDHEESH VACCINES BUSINESS

Managing Director London headquartered GlaxoSmithKline (GSK) started its
journey in India in 1924 to become one of the leaders in the
pharmaceutical industry with a rich healthcare heritage. For
FY18-19, the revenue generation for GSK India in the vaccines
space was recorded at Rs 972 crore, marking a growth of 8 per
cent in comparison to Rs 898 crore generated in FY17-18.
In the area of preventive healthcare, GSK continues to be the
number one vaccines company in the private vaccines market
in India. The vaccines are currently labelled and packaged at the
company’s Nashik facility which has made significant progress
specifically in Quality, EHS (Environmental, Health, and Safety)
and Manufacturing. The Company is upgrading the Nashik site by
investing in infrastructure across all areas with special focus on Good
Manufacturing Practices (GMP), Safety and Sustainability. Over 4500
people work in GSK’s advanced manufacturing facilities, offices and
field across India.
To meet the growing demand for quality medicines in India,
GSK is investing up to Rs 1,000 crores in a new ‘state of the art’
pharmaceutical factory in Bengaluru. The new site will be the first
Greenfield pharmaceutical site GSK has built across the globe in the
last ten years.
Also with opportunities in India opening up, GSK India is aligning
itself with the parent company in areas such as clinical trials, clinical
data management, global pack management, sourcing raw material
and support for business processes including analytics. GSK has a
Clinical development operations centre in Bengaluru (CDOC – B)
that houses more than 100 staff working in Data Handling, Study
Set Up, Scientific and Public Disclosure, Biometrics, Quality Risk
Management and Clinical Project Management.
GSK’s vaccines business is one of the largest in the world,
producing paediatric and adult vaccines against a range of infectious
diseases. Around 40 per cent of the world’s children are immunised
against at least one serious disease with a GSK vaccine. With 14
different brands of vaccines, GSK is currently addressing a number
of diseases such as influenza, chickenpox, hepatitis A and B, rabies,
meningitis etc. across the globe.
GSK globally employs over 99,000 people in 150 countries, and
has an extensive network of manufacturing sites and R&D centres in
36 countries and major R&D centres in the UK, USA, Spain, Belgium
and China. As a recent development in the vaccines space, GSK has
introduced breakthrough vaccines Shingrix for shingles and Bexsero,
the first vaccine for meningitis B in the global market.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 25

05

SANOFI INDIA LTD

REVENUE INNOVATING SOLUTIONS IN
PREVENTIVE HEALTHCARE
₹ 948 crore
Present in India since 1956, Mumbai based Sanofi India
N RAJARAM recorded a revenue of Rs 948 crore in the biologics space
in the FY18-19 as compared to Rs 842 crore in the FY17-
Managing Director 18, leading to a growth of 13 per cent. Sanofi Pasteur, the
vaccines division of the French multinational company
Sanofi, is a world leader in the vaccine industry and a key supplier
of life-saving vaccines all over the world. Contributing to keeping
India polio- free, every second child in India receives Sanofi Pasteur’s
inactivated polio vaccine.
In India, Sanofi has a Chemistry & Biotechnology development
centre in Ankleshwar, manufacturing intermediates and APIs and
pharmaceuticals. There is also a formulations development centre
located in Goa running 35 bioequivalence studies and 17 patents to
its credit, along with manufacturing pharmaceuticals. An affiliate
of Sanofi Pasteur, Shantha Biotechnics represents the R&D and
manufacturing unit for the vaccines business in Hyderabad.
The Vaccines R&D portfolio at Sanofi includes 11 vaccines and
antibodies currently in advanced development. Out of these, Sanofi
is developing a paediatric hexavalent vaccine designated as Shan 6
for the Indian market and other low and middle income countries.
The vaccine targets the prevention of Haemophilus influenza type B,
diphtheria, tetanus, pertussis, hepatitis B and poliomyelitis infections.
The vaccine is currently in its phase III trial.
The FY18-19 saw Sanofi receiving WHO pre-qualification for its
standalone IPV (Inactivated Polio Vaccine) – ShanIPV, developed by
its affiliate Shantha Biotechnics. This status qualifies ShanIPV vaccine
for purchase by the United Nations’ agencies. Marking another
achievement, Sanofi Pasteur launched its 4-strain influenza vaccine
FluQuadri in India in July 2018. FluQuadri is India’s first quadrivalent
vaccine that will provide broader protection against all four strains of
influenza viruses. On the other hand, Sanofi Genzyme, the specialty
care global business unit of Sanofi, brought to India in August 2018,
Aubagio for the treatment of Multiple Sclerosis (MS). As part of its
Corporate Social Responsibility (CSR), Sanofi India has joined hands
with the Directorate of Health Services, Government of Goa, to build
awareness of diabetes and its management
Sanofi is a global healthcare leader that discovers, develops
and distributes therapeutic solutions focused on patients’ needs.
Sanofi is organized into five global business units: Diabetes and
Cardiovascular, General Medicines and Emerging Markets, Sanofi
Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in
Paris and in New York.

26 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

06

RELIANCE LIFE SCIENCES PVT LTD

REVENUE PRIORITIZING
COMPETENCY DEVELOPMENT
₹ 850 crore
For the FY18-19, Reliance Life Sciences (RLS) recorded a revenue
“Reliance Life Sciences being a private generation of Rs 850 crore in the biologics space as compared
limited company does not place its to Rs 708 crore generated in the previous financial year FY17-
18, exhibiting a growth of 20 per cent.
financials in the public domain. Reliance Reliance Life Sciences is part of the Promoter Group of
Life Sciences ended the financial year Reliance Industries Limited. RLS was established to develop business
2018-19 on an excellent note. Reliance opportunities in medical biotechnology with key initiatives in
biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical
Life Sciences took rapid strides in terms research and molecular diagnostics. From a domain perspective, these
of new product and clinical development, Biopharmaceuticals business include Plasma Proteins, Biosimilars
higher manufacturing capacities, greater (Recombinant Proteins, Monoclonal Antibodies) and Novel Proteins.
The company currently has 7 products in the plasma proteins
market participation and new out- portfolio that are manufactured at the company’s in-house in
licensing partnerships. RLS envisages the cGMP facilities. RLS has one pilot scale facility for Plasma Proteins in
Mumbai, one commercial scale facility for Recombinant Proteins and
new financial year 2019-20 to be even Monoclonal Antibodies (mammalian and microbial cell culture and fill
better, on the strength of entry into finish for vials and syringes), one commercial scale facility for Plasma
the larger regional markets, additional Fractionation, and another commercial scale facility for Plasma
manufacturing capacities coming on Proteins at Dhirubhai Ambani Life Sciences Centre, Navi Mumbai.
stream, better value chain integration, These facilities conform to Indian FDA, WHO-GMP, EMEA and USFDA
several new clinical trials, many more standards. On the biosimilars front, the company currently markets
new products across all businesses around 16 different biosimilars in India and overseas markets. These
and forays into innovative technology products are manufactured in-house in a commercial scale facility
for Recombinant Proteins and Monoclonal Antibodies at Dhirubhai
domains.” Ambani Life Sciences Centre, Navi Mumbai.
RLS is also developing novel therapeutics for treatment of cancer,
KV SUBRAMANIAM infectious diseases, inflammatory disorders, ocular disorders and
neurodegenerative disorders. The discovery programme is based on
President siRNAs and monoclonal antibodies. In the domain of monoclonal
antibodies, a number of validated targets have been identified for the
development of antibody-based therapeutics. These targets are both
cell surface receptors and soluble proteins, which are implicated in
cancer and inflammatory diseases. Through these research activities,
the company aims at bringing cost-effective therapies for the benefit
of the global population.
In addition, the company has established Reliance Institute of
Life Sciences,dedicated to specific areas of fundamental and applied
research that include basic and applied life sciences, bio/pharmaceutical
science and engineering, process development, manufacturing science,
quality management and clinical research. So far, it has filed over 360
patents at national and international levels and 126 patents have been
granted covering the entire spectrum of its R&D activities.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 27

07

BHARAT BIOTECH INTERNATIONAL LTD

REVENUE AIMING FOR A
BIGGER PORTFOLIO
₹ 774 crore
Arevenue generation of Rs 774 crore has been recorded
“The Company is poised for a significant for Bharat Biotech (BB) in the vaccines and biologics
growth in the next financial year in space for FY18-19. This marks a 10 per cent growth for the
terms of Revenue and Profitability, company in comparison to the revenue generation a year
which would essentially come from before which was summed up at Rs 705 crore (FY17-18).
In February 2019, Bharat Biotech has acquired 100 per cent equity
increased supplies to both domestic and stake in Chiron Behring Vaccines, one of the largest manufacturers
international markets. In addition, the of high quality rabies vaccines in the world located in Ankleshwar,
Gujarat from GlaxoSmithKline Asia.
Company is also planning to launch new
vaccines. In our endeavour towards a Relentless innovation at Bharat Biotech has made it the first
Indian company to develop successful vaccine candidates against
healthier world, we are honoured to be Rotavirus, Typhoid, Zika, and Chikungunya infections through its
playing a small part in the advancement own dynamic R&D. The company’s latest products, Typbar TCV®
and ROTAVAC®, have been WHO Pre-Qualified and well-received
of health sciences.” globally and are being extensively used in improving global public
health. Typbar TCV® is the first clinically proven Typhoid Conjugate
DR KRISHNA ELLA Vaccine in the world. It became the first new vaccine from India to
be recommended by the WHO for routine immunization of children
Chairman and Managing Director globally against typhoid fever.

Bharat Biotech came into existence in 1996. Within two years, the
company had successfully launched world’s first Cesium Chloride
free Hepatitis B vaccine Revac-B+. Moving on, the company became
the largest manufacturer of Hepatitis B vaccines in the world. Bharat
Biotech’s first bio-therapeutic product came soon after in 2001.
BB is also the first Indian company to receive two grants from the
Bill & Melinda Gates Foundation through Program for Appropriate
Technology in Health (PATH) to develop new vaccines against Malaria
and Rotavirus.

The company has 13 vaccines products and five therapeutics
products in its portfolio. With 160 patents in its kitty, BB is
currently working on developing 8 new vaccines and 3 new
therapeutics products. Research is being carried out on bio-
antibiotics, combination probiotics, Lysostaphin, and recombinant
Staphylokinase injection (THR-100); and vaccines for Chikungunya,
rotavirus, malaria, liquid rabies and Staphylococcus Aureus.

All anti-viral bacterial and recombinant vaccines are manufactured
at the company’s world-class manufacturing facility in Genome Valley,
Hyderabad. The largest facility of its kind in the Asia-Pacific region,
this state-of-the-art plant conforms to the standards set by global
regulators like SFDA, UKMCA, KFDA, NRA and WHO. Central to the
company’s research approach is a collaborative attitude to engaging
with world-class research institutions on shared priorities.

28 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

REVENUE 08

₹ 708 crore INTAS PHARMACEUTICALS LTD

BINISH CHUDGAR COMMITTED TO
BIOLOGICS BUSINESS
Managing Director
Ahmedabad based Intas Pharmaceuticals recorded a
revenue of Rs 708 crore in the biologics space during
FY18-19 exhibiting a huge growth of 60 per cent from
the last fiscal’s revenue at Rs 443 crore. Besides well-
established domestic prominence, Intas is also present in
more than 80 countries worldwide with robust sales, marketing and
distribution infrastructure in markets like North America, Europe,
Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as
well as CIS and MENA countries.

The product portfolio consist of 11 commercialized products,
8 rDNA products including 1 monoclonal antibody, and 3 plasma
derived products. In addition the company has 12 new products
in its pipeline. Intas has made a substantial commitment to its
Biologics Business Unit in terms of creating R&D, manufacturing and
marketing capabilities for its biotech portfolio. It is the first company
to launch a biosimilar in EU (Filgrastim & Peg-filgrastim) as well as the
first company to launch patented aqualip technology based delivery
system in India. It is India’s first biosimilars manufacturing unit to
receive European Union - Good Manufacturing Practice (EU-GMP)
certification for the Drug Substance (microbial) and Drug Product
manufacturing facilities, attesting to highest quality of manufacturing
and quality systems. In addition to the EU-GMP, Intas’ Biological BU
facilities are approved by various other regulatory agencies such as
ANVISA, GCC, MCC, Indonesia, etc.

Intas is one of the fastest growing Indian company in the biosimilar
space with 13 commercialized biosimilars including Docetaxel &
Paclitaxel. The company also operates in the field of Plasma derived
products and therapies with proven technical capabilities. The
current product portfolio has 3 products and there are several others
under development. In addition, the company also has an animal
health business unit split into two SBUs (Neovet & Bovicuraa) based
on customers and market need verticals. Being the fastest growing
Animal Health Company in India, Intas also enjoys the distinction of the
fourth largest player in the livestock business segment.

The company operates nine formulation manufacturing facilities,
of which seven are located in India, and the rest in the U.K. and
Mexico. It also operates two API and intermediate manufacturing
facilities, each of which complies with the regulatory requirements in
the jurisdictions in which it operates.

At present, Intas continues its R&D efforts in chronic disease areas
such as oncology (cancer), rheumatology, auto-immune, nephrology,
ophthalmology and plasma derived product based therapies.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 29

BIOLOGICAL E LTD 09

REVENUE MAKING DISEASE PREVENTION
A DISTINCT REALITY
₹ 672 crore
For FY18-19, Hyderabad based Biological E (BE) showed a
MAHIMA DATLA revenue generation of Rs 672 crore as compared to Rs 504
crore in the previous FY17-18, displaying a growth of 33 per cent
Managing Director in the vaccines space. The company currently has 11 vaccines
products in its portfolio and a few under development.
Set up in 1953, BE has a formidable presence in vaccines, sera and
other biologics, and pharma. Over the years, BE has extended its vaccine
portfolio, invested in cGMP manufacturing facilities and built new state-
of-the-art facilities and a modern infrastructure to ensure future growth
and the development of new products. BE facility at Genome Valley,
Hyderabad is one of the largest biotech manufacturing sites in Asia. The
company has recently invested to introduce two new processing suites
and expand current production and product testing capabilities for a
number of products. BE also has a dedicated clinical research facility
focused on Epidemiologic and behavioural studies, Outcomes research
and health services research, and Patient-oriented research.
BE supplies several essential and lifesaving Vaccines and
Pharmaceuticals to UN Agencies viz. UNICEF, Pan American Health
Organisations, other global markets and within India to Central and
State Government Hospitals, Public Sector Undertakings, the Indian
Armed Forces and the domestic retail market. BE supplies more than
60 per cent of its paediatric vaccines to the Government of India.
In addition, BE has established productive partnerships with
several well respected and renowned Institutions and Public Health
Services across the world namely Nederlands Vaccine Institute (NVI),
Netherlands for Haemophilus Influenzae - B vaccine (Hib); Intercell
AG, Austria for Japanese Encephalitis (JE) vaccine; National Institute of
Health (NIH), U.S.A for Dengue and Rota Virus vaccines; Indian Institute
of Science (IISc), Bengaluru for obtaining Hepatitis - B technology;
and International Centre for Diarrhoeal Disease Research (ICDDR),
Bangladesh for cholera vaccine.
At present, Biological E is developing an IPV vaccine and is expected
to start Phase 1 trials in India this year. The company has also entered
into a technology transfer arrangement with Novartis Vaccine Institute
for Global Health (NVGH) for typhoid conjugate vaccine. In addition
to the typhoid conjugate vaccine, NVGH has licensed paratyphoid
vaccine technology to Biological E. Simultaneously, the company is
also developing a pneumococcal conjugate vaccine comprising of 14
pneumo serotypes. BE has also partnered with GlaxoSmithKline to
develop liquid hexavalent vaccine. The vaccine comprises of diphtheria,
tetanus, whole cell pertussis, inactivated polio, haemophilus influenzae
type B and hepatitis B.

30 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

REVENUE 10

₹ 600 crore BHARAT SERUMS AND VACCINES LTD

BHARAT V. DAFTARY BRINGING PATH
BREAKING PRODUCTS
Chairman & Managing Director
Mumbai based biopharmaceutical company Bharat
Serums and Vaccines (BSV) recorded a revenue
of Rs 600 crore this fiscal FY18-19 in the biologics
and vaccines space, as compared to Rs 540 crore
in the previous year, marking a growth of 10 per
cent. Founded in 1971, the company has a product portfolio of 25
brands which include plasma derivatives, monoclonal, fertility
hormones, antifungals, anesthetics, cardiovascular drugs and
equine immunoglobulin antitoxins. The products are sold through
six specialty areas namely Gynecology; Assisted Reproductive
Technology; Critical Care; Emergency Medicine; Urology; Neurology,
Nephrology & Haematology. BSV has an injectable plant located
Ambernath, Maharashtra housing 4 dedicated injectable lines
targeting India and emerging markets. Ambernath also stations
a Biotech API & Injectable plant which is focused on biological
and biotech products. The plant has capabilities to manufacture
commercial scale mammalian cell cultured derived recombinant
proteins and fill and finished capabilities for liquid and lyophilized
injectable products. The company also has a horse farm in
Maharashtra, with facilities for the immunization of animals,
plasmapheresis, plasma separation and on-site testing under the
supervision of qualified veterinary doctors.
BSV started its international business operations in early 2000.
The international business operation got a major boost with the
commissioning of the new Ambernath plant in 2003. Integrated
with a sound manufacturing facility at Ambernath and an efficient
regulatory team, BSV has seen an exponential rise in its revenues
accruing from international business operations over the years. The
Company’s products are registered in more than 45 countries and
its manufacturing facilities are accredited and certified by various
regulatory authorities from Asia, Latin America, Middle East, Africa,
etc. BSV has its liaison offices in Russia, Philippines, Vietnam, Nigeria,
Ukraine and also has country managers based in various countries in
Asia Pacific, Russia CIS, Latin America and Africa. BSV also works with
international health agencies such as the World Health Organization
(WHO), Pan American Health Organization (PAHO) and the Ministry
of Health of various countries.
In addition, a 100 per cent subsidiary of BSV, BSV BioSciences Inc
has developed cell lines and lab scale processes for two biosimilar
products and two first-in the world products. These products are in
various stages of clinical development and commercialization.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 31

11 The Indian business of American multinational
pharmaceutical corporation Pfizer recorded a revenue
PFIZER LTD generation of Rs 579 Crore in the biologics space during
FY18-19, showing a decline by 7 per cent when compared to
REVENUE the revenue figures in FY17-18 which stood at Rs 619 Crore.
In India, Pfizer is one of the select companies called upon to
₹ 579 crore provide recommendations on operationalizing the National
Action Plan on AMR by the WHO and the Government of
S SRIDHAR India in 2018. Its partnership with Indian Council of Medical
Research (ICMR) – to set up a Centre to Combat AMR – is the
Managing Director first of its kind in the country. Headquartered in Mumbai,
Pfizer India got started in 1950. With over 4,000 colleagues
spread across India, Pfizer has five state-of-the-art
manufacturing facilities located at Maharashtra and Tamil
Nadu. However, the company intends to soon shut down two
manufacturing sites located in Aurangabad, Maharashtra
and Irungattukottai (IKKT) near Chennai affecting 1700
employees working at these two locations. In India, Pfizer
instituted the first ever Disease Management Programme
-- Healthy Heart in Cardio Vascular Disease (Hypertension,
Chronic Stable Angina and Dyslipidemia), in partnership with
Apollo Hospital, Hyderabad and Apollo Hospital, Chennai.
The product portfolio at Pfizer India comprising of more
than 100 products is spread across a large number of sectors
namely allergy, diabetes, infectious diseases, cardiovascular,
dermatology, etc.

INDIAN 12 Hyderabad based vaccine manufacturer Indian
IMMUNOLOGICALS Immunologicals (IIL) recorded a revenue of Rs 535
LTD crore in FY18-19 in the vaccines space exhibiting
a growth of 16 per cent from the last fiscal’s revenue at
REVENUE Rs 460 crore. The company also generated a revenue of
Rs 69.6 crore in the other space including its contract
₹ 535 crore manufacturing business during FY18-19. IIL is the market
leader in veterinary biologicals in India and operates one
DR K ANAND KUMAR of the largest plants in the world for veterinary vaccines.
IIL manufactures vaccines for animals and humans at its
Managing Director manufacturing facilities located in Karakapatla, Telangana
and Ooty, Tamil Nadu. In 2018, the company launched
VAXTAR 5, a pentavalent vaccine (Diptheria, Pertussis,
Tetanus, Hepatitis B and HiB) for children. IIL was setup by
The National Dairy Development Board (NDDB) in 1982, as
its unit, with the objective of making vaccines available to
farmers at an affordable price. The unit was corporatized
as Indian Immunologicals Limited in the year 1999. The
company started manufacturing human vaccines in 1998
at the specific request of the Government of India. IIL is the
second company in the world and first in India to launch
the purified Vero cell rabies vaccine (PVRV) with the brand –
Abhayrab. This led to the discontinuation of use of the older
and unsafe sheep brain vaccine (also termed nerve tissue
vaccine – NTV) in the country.

32 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

13 Mumbai based Macleods Pharmaceuticals recorded
a revenue of Rs 406 crore during the FY18-19 in the
MACLEODS biologics space, showing a growth of 20 per cent
PHARMACEUTICALS from the previous financial year 2017-18 where the revenue
PVT LTD count was Rs 338 crore. With an experience of more than
2 decades, Macleods is an established name in Indian
REVENUE Pharmaceutical market. With its diversified product portfolio,
Macleods has gained leadership in various therapeutic
₹ 406 crore segments. The company’s product portfolio encompasses a
wide spectrum of therapeutic groups, ranging from Anti-TB,
RAJENDRA AGARWAL Asthma & COPD, Anti-bacterial, NSAID, Anti-arthritic, Anti-
osteoporotic, Gastroenterology, Gynecology, Diabetology
Managing Director and CVS products. The R & D centre at Macleods is located in
Mumbai, which was setup in the year 2000, and is approved
by the Department of Scientific and Industrial Research,
Government of India. Besides that, the company also has a
Bioequivalence department established in 2005. Its clinical
and bio-analytical facilities and processes, are inspected by
the Drugs Controller General of India (DCGI), US FDA, WHO
and MCC (South Africa). In addition, the manufacturing
facilities at Macleods are approved by international
regulatory agencies including USFDA, UK-MHRA, WHO-
Geneva, MCC South Africa, MOH - Saudi Arabia, MOH- UAE,
MOH- Belarus, MOH- Ukraine, INVIMA- Colombia, National
Drugs Authority (NDA) Uganda, Food and Drugs Board,
Kenya; Pharmacy Board, Tanzania FDA, etc.

14 For the FY18-19, Mumbai based Lupin recorded a
revenue generation of Rs 381 crore in the biologics and
LUPIN LTD insulin space as compared to Rs 345 crore generated
in the previous financial year FY17-18, exhibiting a growth
REVENUE of 10 per cent. The FY18-19 saw some major developments
taking place at Lupin such as the partnership with AbbVie
₹ 381 crore to develop and commercialize novel oncology drug to
treat hematological cancers; extending partnership with
VINITA D GUPTA Eli Lilly aimed at widening access to innovative diabetes
medicines in India; launch of India’s first chatbot for patients
Chief Executive Officer (CEO) named ‘ANYA’ specially designed to provide medically
verified information for health-related queries; expansion
of collaboration with Boehringer Ingelheim India for co-
marketing of two oral anti-diabetic drugs; tie-up with
European Association of Urology (EAU); launch Anti-TB
Campaign in Mumbai; and signing of an agreement with
CSIR-National Chemical Laboratory and Department of
Science and Technology for conducting research on a
continuous purification process development of a biosimilar
monoclonal antibody therapeutic. The core business at
Lupin comprise of biologics, insulin, API, formulations,
consumer healthcare focusing on Cardiovascular,
Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective, Anti-
TB space. The Biotech unit at Lupin was set up in 2008 with a
vision to produce high-quality biologics more affordable and
accessible to the patients globally.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 33

15 Arevenue generation of Rs 371 crore has been recorded
for Mumbai based Abbott India in the vaccines
ABBOTT INDIA LTD and biologics space for FY18-19. This marks a 29
per cent growth for the company in comparison to the
REVENUE revenue generation a year before which was summed
up at Rs 288 crore (FY17-18). The FY18-19 witnessed few
₹ 371 crore major developments unfolding at Abbott India such as
the launch of a new digital service in India as part of its
AMBATI VENU global A:Care programme; and collaborating with the
government of Odisha for providing technology, expertise
Managing Director and funding support to advance efforts to end malaria in
the state. The Indian subsidiary of the American healthcare
company Abbott Laboratories came into existence in
1910. Abbott in India develops and distributes over 600
products distributed among therapy areas such as
diabetes, cardiovascular, respiratory, hepatic, neuroscience,
metabolics, gastrointestinal. Abbott India entered into the
vaccine space in 2014, and currently has five products in the
portfolio, including vaccines to prevent influenza, typhoid
conjugate, rotavirus, Japanese encephalitis, and a whole cell
pentavalent vaccine to protect people against five critical
diseases. The company also has strategic alliance with
Bharat Biotech to market its four vaccines under Abbott
brand names in the domestic market.

SHANTHA 16 Arevenue generation of Rs 369 crore has been recorded
BIOTECHNICS for Hyderabad based Shantha Biotechnics during
PVT LTD FY18-19 in the vaccines space. Shantha Biotechnics
is a wholly owned subsidiary of Sanofi group which
REVENUE was founded by Dr Varaprasad Reddy in 1993. Shantha
became the first Indian company to market a recombinant
₹ 369 crore human healthcare product, by solely developing and
commercializing vaccine r-DNA Hepatitis-B. Shantha
DR MAHESH BHALGAT produces vaccines against Hepatitis B, Tetanus, Diphtheria,
Pertussis, Haemophilus Influenzae type b conjugate, and
Executive Director Cholera. Four of the licensed vaccines at Shantha are WHO-
prequalified: Shan5 pediatric vaccine, Shanchol cholera
vaccine, Shanvac-B hepatitis B vaccine, and ShanTT tetanus
vaccine. In October 2018, Shantha’s Inactivated Polio Vaccine
– ShanIPV also received prequalification by the World Health
Organization (WHO). The company has become the first
to partner with the Indian Government for IPV since India
was declared polio-free. The manufacturing operations
at Shantha are based out of Hyderabad and support the
supply of the products to more than 100 countries globally.
Using state-of-the-art equipment, the manufacturing team
works hand in hand with Research and Development team
to provide the highest quality products to the market. There
are around 65 employees working at R&D facility that has
50,000 sq.ft of laboratory area, divided into four independent
laboratories.

34 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

17 Ahmedabad based pharmaceutical company Zydus
Cadila Healthcare recorded a revenue of Rs 362
ZYDUS CADILA crore in FY18-19 in the biologics and vaccines space,
HEALTHCARE LTD as compared to Rs 340 crore in the previous year FY17-
18, marking a growth of 7 per cent. FY18-19 saw Zydus
REVENUE entering into a partnership with the Council of Scientific and
Industrial Research (CSIR) - Institute of Microbial Technology
₹ 362 crore (IMTECH), for development of newer drugs for drug-resistant
infectious diseases. Zydus’ global business has a strong
presence in the regulated markets of the US, Europe (France
and Spain) and in the high profile markets of Latin America
and South Africa. The India Business comprises the India
formulations business spearheaded by Zydus Healthcare
Ltd., based in Mumbai and the Biologics business which
drives the sales and marketing of biosimilars and novel
biologics. In addition, the Vaccine Technology Centre (VTC)
is the vaccine research centre of the Zydus Group. VTC has
two state-of-the-art R & D Centers, one located in Catania,
Italy and the other in Ahmedabad, in the western part of
India. Zydus has indigenously developed, manufactured
and launched India’s first Tetravalent Inactivated Influenza
vaccine, VaxiFlu – 4. Zydus’ rabies vaccine manufacturing
facility has received WHO pre-qualification, and is one of the
largest rabies manufacturing facilities in India.

PANKAJ R PATEL

Chairman

18 Baxter India, a wholly owned subsidiary of US based
Baxter International Inc. witnessed a revenue of Rs
BAXTER INDIA 300 crore during the FY18-19 in the biologics space,
PVT LTD showing a growth of 20 per cent from the previous financial
year 2017-18 where the revenue count was Rs 250 crore. The
REVENUE company primarily focuses on products to treat hemophilia,
kidney disease, immune disorders and other chronic and
₹ 300 crore acute medical conditions. Baxter started its operations in
India in 1997. Currently, Baxter India’s commercial operations
RAVINDER DANG and Global operations e.g. Centre of Excellence, Global
Delivery Centre, Global Learning Centre are run through the
General Manager corporate office located in Gurugram, Haryana. Baxter also
has a R&D centre in Bengaluru which was set up in 2014.
In addition, the company’s Ahmedabad facility is broadly
focused on generic injectables. Baxter formulates, fills and
finishes a broad portfolio of essential generic medicines with
complementary strengths in anesthesia and analgesics,
critical care and renal medicines, and anti-infectives in a
variety of presentations including bags, vials and ampules.
However, 2018 saw Baxter receiving a warning letter from the
USFDA for violating current good manufacturing practice
norms at its Ahmedabad plant.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 35

VENTRI 19 For the FY18-19, Ventri Biologicals recorded a revenue
BIOLOGICAL generation of Rs 250 crore in the animal vaccines space
PVT LTD as compared to Rs 230 crore generated in the previous
financial year FY17-18, exhibiting a profit of 9 per cent. Ventri
REVENUE Biologicals, a vaccine division of Pune based Venky’s (India)
Limited, is a leader in poultry vaccines business in India.
₹ 250 crore Started in 1980, the division produces vaccines for Marek’s
disease and Newcastles’s disease. The plant was built in
collaboration with Tri Bio Laboratories Inc. of USA, a world
leader in vaccine technology and research. Its vaccine plant
is acknowledged as one of the most modern plants and is
capable of meeting the demands of the projected growth of
the Indian poultry industry. Backed by extensive and modern
research and development facilities, Ventri Biologicals
is constantly engaged in developing new generation
vaccines, to combat emerging bacterial and viral diseases.
It produces vaccines conforming to British Pharmacopeia
and other international standards. The division works in close
association with the Poultry Diagnostic and Research Centre
in Andhra Pradesh that provides the technical service and
carries out disease surveillance across the country. Ventri
Biologicals provides a wide range of 32 poultry vaccines,
some of which have been introduced for the first time.

ANURADHA JITENDRA DESAI

Chairperon

20 For the FY18-19, Sun Pharma Industries Ltd (SPIL) earned
a revenue generation of Rs 237 crore in the biologics
SUN PHARMA and vaccines space as compared to Rs 218 crore
INDUSTRIES LTD generated in the previous financial year FY17-18, exhibiting
a profit of 9 per cent. These numbers includes the sales of
REVENUE biologicals of Ranbaxy’s brands as well which is now part of
Sun Pharma. Mumbai headquartered Sun Pharma’s global
₹ 237 crore presence is supported by 47 manufacturing facilities spread
across 6 continents, R&D centres across the globe and a
DILIP SHANGHVI multi-cultural workforce comprising over 50 nationalities.
The company has around 2000 research scientists working
Managing Director in multiple R&D centres located in Vadodra, Mumbai,
Gurugram in India, and 4 in the US. These centres are
equipped with cutting-edge enabling technologies for
research with expertise in developing generics, difficult to
make technology intensive products, Active Pharmaceutical
Ingredients (APIs), Novel Drug Delivery Systems (NDDS)
and New Chemical Entities (NCEs). Sun Pharma has joined
hands with Pune based National Institute of Virology (NIV) to
test new medicines developed by the company to combat
zika, chikungunya and dengue diseases. In addition, the
company has collaborated with International Centre for
Genetic Engineering and Biotechnology in New Delhi for
development of a dengue vaccine, targeted against all
the four serotypes of Dengue virus that cause disease in
humans.

36 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

PANACEA New Delhi based Panacea Biotec generated a revenue of
BIOTEC LTD Rs 218 crore in the vaccines space in the FY18-19 marking
a growth of 17 per cent when compared to the revenue in
REVENUE 21 FY17-18 which was recorded at Rs 186 crore. Panacea Biotec
is one of the largest Vaccine Manufacturing Companies in
₹ 218 crore India and is well acknowledged by the UN Health Agencies in partnering
the Polio eradication initiative with supplies of millions of doses of WHO
DR RAJESH JAIN Pre-qualified Polio vaccine. It is the first company to have developed
fully liquid Pentavalent vaccine (DTwP+Hep B+Hib). It is currently
Managing Director working on developing vaccines for Anthrax, Dengue, Japanese
encephalitis among others. In 2018, Panacea Biotech signed a historic
deal with Serum Institute of India Pvt. Ltd. (SII) and SII’s wholly owned
subsidiary, Bilthovan Biologicals B.V. (BBIO) to manufacture & sell fully
liquid Whole cell Pertussis (wP) and Salk based Injectable Polio Vaccine
(IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV) developed &
commercialized by Panacea Biotec.

WOCKHARDT LTD For the FY18-19, Mumbai based Wockhardt Ltd recorded a
revenue of Rs 197 crore in the biologics and vaccines space in
REVENUE 22 India, showing a decline of 11 per cent from last year’s revenue
at Rs 221 crore. With 3 research centres and 12 manufacturing
₹ 197 crore plants, Wockhardt’s business ranges from the manufacture and
marketing of Pharmaceutical and Bio-pharmaceutical formulations,
DR MURTAZA Active Pharmaceutical Ingredients (APIs) and Vaccines. More than 60
KHORAKIWALA per cent of the revenue is generated through international business.
The company’s pioneering efforts in biotechnology have led to the
Managing Director launch of three successful products in the Indian market - Glaritus
(long-acting 24-hr insulin analog), Wosulin (recombinant insulin), Wepox
(erythropoietin) and Biovac-B (hepatitis B vaccine). The company also
has a biotechnology park commissioned in 2004 comprising of six
dedicated manufacturing facilities. Wockhardt is also in the forefront of
Intellectual Property creation with 1,733 patents filed till date, of which
228 patents have been granted.

EMCURE The revenue generation for Pune based Emcure
PHARMACEUTICALS Pharmaceuticals was Rs 181 crore during FY18-19 in biologics
LTD space in comparison to Rs 170 crore generated in FY17-18,
showing a growth of 6 per cent. The company has a portfolio of
REVENUE 11 chiral molecules, eight of which were launched for the first
time in India. Emcure has 8 brands covering various therapeutics areas
₹ 181 crore 23 related to blood, oncology, HIV, gynecological, cardiac, ani-infectives.
Its subsidiary Gennova Biopharma, incorporated in the year 2001, is
SATISH involved in developing, manufacturing and marketing biotechnology
based products required for humans and veterinary purposes in India
RAMANLAL and abroad. Emcure’s R&D activities are spread across its nine dedicated
facilities located in Pune, Ahmedabad and New Jersey. Out of the 9 R&D
MEHTA centres, two are focused towards API research, five towards formulations
and two towards biotechnology research. The R&D team is comprised of
Chief Executive Officer 500 highly qualified scientists including post-doctorates, PhD holders
and post-graduates. On the other hand, Emcure’s manufacturing
operations are spread across 11 facilities globally.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 37

ELI LILLY & CO Gurgaon headquartered Eli Lilly and Company (India), a wholly
(INDIA) PVT LTD owned subsidiary of US based biopharmaceutical firm Eli Lilly and
Company recorded a revenue of Rs 161 crore in the biologics space
REVENUE 24 during FY18-19, growing by 14 per cent as compared to Rs 141 crore
generated during FY17-18. Lilly India marked its 25 year presence
₹ 161 crore in India in 2018. Since its inception in India in 1993, the company has been
committed to developing and marketing pharmaceutical products to treat
LUCA VISINI diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men’s
health and growth-hormone deficiency. Lilly India affiliate also comprises
Managing Director operations in neighboring countries of Nepal, Bangladesh and Sri Lanka.
The company opened the Lilly Capability Centre India (LCCI) in Bengaluru
in January 2016. This centre allows Lilly to take advantage of unique drug
development capabilities found in India. The company‘s work in India also
encompasses partnerships in MDR TB, Diabetes and Hypertension, as well as
community volunteering projects through Global Day of Service, Connecting
Hearts Abroad and a non-formal education centre called STEP UP.

FRESENIUS KABI Pune based Fresenius Kabi India, a 100 per cent subsidiary of
INDIA PVT LTD Fresenius Kabi AG Germany, recorded a revenue generation of
Rs 145 crore in the biologics space during FY18-19, exhibiting a
REVENUE 25 growth of 5 per cent when compared to revenue generation
in FY17-18 recorded at Rs 138 crore. Established in 1995,
₹ 145 crore Fresenius Kabi India deals in clinical nutrition; IV drugs which formulate
intravenously administered generic drugs such as Oncology drugs,
SANJAY GUPTA Anesthetics & Analgesics, Anti-infective & Critical Care drugs; Infusion
therapy that includes infusion solutions & colloids; Medical Devices
Managing Director (Transfusion Technology/Infusion Technology) offers pumps, disposables,
(South Asia) Infusion management system, products of collection & processing of
blood components & for therapeutic treatment of patients blood by
apheresis systems. In the field of biosimilars, the company develops
products with a focus on autoimmune diseases and oncology. All
these therapeutic areas are segmented in 9 different business verticals
functioning across various geographies.

BRILLIANT BIO The revenue generation for Hyderabad based Brilliant Bio Pharma
PHARMA PVT LTD (BBP) was Rs 140 crore in the animal vaccines space during
FY18-19. The business grew by 8 per cent in comparison to the
REVENUE 26 revenue figures during FY17-18 recorded at Rs 130 crore. BBP
has its presence in Veterinary Biologicals comprising of viral
₹ 140 crore vaccines against foot-and-mouth disease (FMD) and rabies, bacterial
vaccines against Haemorrhagic Septicaemia (HS), Blackquarter (BQ)
MOURYA BODA and Enterotoxaemia (ET), and Animal Health Products (AHPs) including
Antibiotics and Antibacterials, Analgesics and Antipyretics, Dewormers,
Chairperson Ecto and Endo Parasiticides, Feed Supplements, Galactogogues etc. The
company is one of the registered suppliers of Veterinary Vaccines and
Medicines to Food & Agriculture Organization (FAO), Rome, Italy and has
exported to DPRK (North Korea), Bangladesh, Chad and Yemen as per FAO
orders. The new products in pipeline are vaccines against Pestes Des Petits
Ruminants (PPR), Goat Pox and Bluetongue. The company also has plans
to enhance the FMD vaccine production capacity up to 300 Million doses
per annum by expanding the manufacturing facilities.

38 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

ABBOTT Mumbai based Abbott Healthcare witnessed a revenue
HEALTHCARE PVT LTD generation of Rs 129 crore in the biologics space during
FY18-19, marking a 5 per cent growth from the last year’s
REVENUE 27 revenue recorded at Rs 123 crore. The majority share of
the revenue from the domestic market was obtained
₹ 129 crore through the hormone based products (around Rs 84 crore) while the
rest is attributed to the blood related products (around Rs 45 crore) in its
portfolio. Founded in 1997, the company offers products in therapy areas
such as respiratory, gastro, dermal, nutritional, parenteral, anti-parasitic,
gynecology, ophthalmology and otolaryngology, oncology, cardiac,
diabetes and hormones.

ASHOK NAIR

Managing Director

HESTER For the FY18-19, Ahmedabad based Hester Biosciences witnessed
BIOSCIENCES LTD a revenue count of Rs 128 crore in the animal vaccines space,
growing by 7 per cent in comparison to the revenue generated
REVENUE 28 in the previous year at Rs 120 crore. The company has a product
portfolio of over 50 vaccines and 35 health products distributed
₹ 128 crore among four verticals: Poultry Vaccines, Animal Vaccines, Poultry Health and
Animal Health. It is the second largest poultry vaccine manufacturer in India.
RAJIV GANDHI The company has a state-of-the-art manufacturing facility unit in Mehsana,
Gujarat, complying with stringent international norms. Hester is WHO-
CEO & GMP, Good Laboratory Practices (GLP), ISO 9001, ISO 14001 & OHSAS 18001
Managing Director certified, also having DSIR (Department of Scientific & Industrial Research)
approval for in-house R&D Department. Driven by a team of 300 employees,
Hester Biosciences has emerged as the first in India to manufacture the
Goat Pox Vaccine. The company has a strong presence in the international
market as well such as Nepal, Bangladesh, Spain, Nigeria, Uganda, to name
a few. Hester plans to reach out to South Korea and Taiwan in the future.

MSD Mumbai based MSD Pharmaceuticals recorded a revenue
PHARMACEUTICALS of Rs 96 crore in the biologics and vaccines space during
PVT LTD FY18-19, exhibiting a sharp decline of 42 per cent when
compared to its performance last year at Rs 166 crore.
REVENUE 29 Through its prescription medicines, vaccines, biologic
therapies, and animal health products, MSD operates in more than 140
₹ 96 crore countries. US based Merck & Co., Inc. is known as MSD outside the United
States and Canada. MSD in India currently operates in various therapeutic
VIVEK VASUDEV areas in human health, including Metabolics, Vaccines, Critical Care,
KAMATH Oncology, Women’s Health, Dermatology, Respiratory, and Primary Care,
and offers a strong and diversified product portfolio of over 35 brands.
Managing Director Since its existence in India, the company has moved quickly in laying
the foundation for a business that is differentiated by its focus through
launching innovative products relevant to India. MSD in India also has
presence in Animal Health via MSD Animal Health with its vaccines facility
located in Pune, Maharashtra.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 39

HAFFKINE BHARAT 31
IMMUNOLOGICALS
30BIOPHARMACEUTICAL AND BIOLOGICALS
CORPORATION LTD
CORPORATION LTD
For the FY18-19, Uttar Pradesh based Bharat
The revenue generation for Mumbai based Immunologicals and Biologicals Corporation
Haffkine Biopharmaceutical Corporation, owned Ltd (BIBCL) witnessed a revenue generation of
by the Maharashtra government, was recorded Rs 84 crore in the vaccines space, thereby doubling
at Rs 85 crore in the biologics and vaccines space, its figures from Rs 35 crore recorded in FY17-18. The
showing a decline of 56 per cent in comparison to company currently manufactures and produces
the revenue count in FY17-18 at Rs 195 crore. Haffkine a range of pharmaceuticals products such as Oral
Ajintha Pharmaceuticals Ltd., a subsidiary of Haffkine Polio Vaccines (OPV Vaccine), Zinc Tablet & Diarrhea
Bio-Pharma, develops a wide range of Bacterial and Management Kit etc. BIBC was established as a Public
Viral vaccines, formulates pharmaceutical products, Sector Unit in 1989.
disinfectants, ointments, injectables, syrups and
mixtures. Haffkine introduced Scorpion Venom
Antiserum for the first time in India.

BIOVET 32 33ZUVENTAS
PVT LTD
HEALTHCARE
Biovet generated a revenue figure of Rs 66 crore LTD
in the animal vaccines space during FY18-19,
growing at 8 per cent in comparison to the Mumbai based Zuventas Healthcare witnessed
revenue recorded in the FY17-18 at Rs 55 crore. Malur, a revenue generation of Rs 57 crore in the
Karnataka based Biovet is an emerging animal health FY18-19 in the biologics space growing by
vaccine producing company. It currently has a world 23 per cent in comparison to the revenue amount
class Foot and Mouth Disease vaccine production recorded during FY17-18 at Rs 46 crore. A part of of
facility as per OIE / WHO / GMP specification. Emcure Pharmaceuticals, Zuventas has its presence
in the biotechnology (Enoxarin, Eporise, Peglast) and
vaccines (Vac T, Zuvirab & Zuvicella) segment. With
more than 100 products in its kitty, Zuventas has 3
manufacturing facilities.

LA RENON 34 35MANKIND
HEALTHCARE
PVT LTD PHARMACEUTICALS
LTD
Ahmedabad based La Renon Healthcare
recorded a revenue generation of Rs 55 The revenue generation for New Delhi based
crore during FY18-19 in the biologics space, Mankind Pharmaceuticals was recorded at Rs 51
dropping by 2 per cent when compared to Rs 57 crore in the biologics space, showing a growth of
crore generated during previous financial year. 7 per cent in comparison to the revenue count in FY17-
The company majorly caters to segments of 18 at Rs 48 crore. Mankind has over 1000 products
Nephrology, Critical Care, Neurological Disorders, being marketed and more than 200 products under
Urology, Gastroenterology, Respiratory and Cardio development. The product portfolio caters to wide
Metabolic. The company’s R&D centre has been range of therapeutic areas such as cardiology,
accorded recognition by the Department of Scientific respiratory, neurology, gastroenterology, diabetology,
and Industrial Research (DSIR), a department of dermatology, opthamology and gynaecology.
the Ministry of Science and Technology under the
Government of India.

40 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

INDOVAX 35 MICRO LABS LTD 36
PVT LTD

Gurugram based poultry biotechnology For the FY18-19, Bengaluru based Micro Labs
company Indovax recorded a revenue generated a revenue of Rs 48 crore in the
generation of Rs 51 crore in the animal vaccines biologics space, showing a decline by 14 per
space during FY18-19, exhibiting a growth of 7 per cent when compared to Rs 56 crore generated in the
cent as compared to the revenue generated at Rs 48 FY17-18. Micro’s product portfolio includes some of the
crore in the FY17-18. The company’s product portfolio topmost brands in various specialties like Cardiology,
contains 12 live vaccines and 11 inactivated vaccines. Diabetology, Anti-infectives, Ophthalmology, Pain,
Incorporated in 1986, the company produces over etc. Its global presence is supported by 14 world class
four billion doses of vaccine annually that cater to the manufacturing facilities approved by USFDA, UK-
needs of the domestic and international markets. MHRA, Health Canada, WHO, TGA Australia, MCC-
South Africa & Medsafe New Zealand and 3 R & D
centres in Bangalore and Mumbai.

36DR REDDY’S 37SAMARTH

LABORATORIES LIFE SCIENCES
LTD PVT LTD

Hyderabad based Indian multinational For the FY18-19, Mumbai based Samarth Life
pharmaceutical company Dr Reddy’s Sciences recorded a revenue count of Rs 35
Laboratories earned a revenue of Rs 48 crore in the biologics space, growing by 25 per
crores in the biologics space, growing by 2 per cent when compared to the revenue generated in
cent in comparison to Rs 46 crore earned in FY17- the FY17-18 at Rs 28 crore. Since its inception in 1963,
18. The company offers a portfolio of products and the company has a built a product portfolio focused
services including APIs, custom pharmaceutical on therapeutics areas such as cardiology, oncology,
services, generics, biosimilars and differentiated neurology, pulmonology, antenatal medicines, IVF
formulations. The major therapeutic areas of focus are medicines, to name a few.
gastrointestinal, cardiovascular, diabetology, oncology,
pain management and dermatology.

SHREYA 38 39PAVIOUR
LIFE SCIENCES
PVT LTD PHARMACEUTICALS
PVT LTD
Mumbai based Shreya Life Sciences (SLS),
the Indian arm of Shreya Group, witnessed During FY18-19, New Delhi based Paviour
a revenue generation of Rs 34 crore in the Pharmaceuticals witnessed a revenue count
biologics space during FY18-19, marking a growth of of Rs 33 crore in the biologics space showing
44 per cent in comparison to the revenue count of Rs a decline by 25 per cent in comparison to the
24 crore in the previous financial year. The company revenue generated in the FY17-18 at Rs 44 crore. The
started its operations in India in 2001 by acquiring company was incorporated in 1998 with the objective
the Pharma Division of Rallis India Ltd., a TATA Group of importing, marketing and distribution of various
company. SLS operates through three Strategic Pharmaceutical specialty products which are not
Business Units- Amadeus, AkuCare and BioLife. indigenously produced.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com COVER STORY 41

39OZONE CIPLA LTD 40

PHARMACEUTICALS During the FY18-19, Mumbai based
LTD pharmaceutical company Cipla generated a
revenue count of Rs 32 crore in the biologics
New Delhi based Ozone Pharmaceuticals space, growing by 3 per cent in comparison to
recorded a revenue generation of Rs 33 crore the revenue generated in the FY17-18. With 44
in the biologics space in the FY18-19, showing a manufacturing sites around the world, Cipla produces
growth of 26 per cent when compared to the revenue more than 50 dosage forms and around 1,500
generated during the FY17-18. Ozone Pharmaceuticals products using cutting-edge technology platforms to
is the formulation based drug manufacturing and cater to 80 markets. Cipla had introduced Propranolol,
marketing company, with a focus across 14 therapy the first beta blocker in India way back in 1972. Since
areas including pain management, nutritional then, the company has developed several products to
supplements, anti-infective, cardiac, diabetes and treat many diseases.
hemostats, etc. The company promotes products and
brands to more than 1,00,000 doctors across India and
Nepal.

GREENSIGNAL 41 CLARIS 42
BIO PHARMA LIFESCIENCES
PRIVATE LIMITED LIMITED

For Chennai based vaccine manufacturer The revenue generation for Ahmedabad based
GreenSignal Bio Pharma (GSBP), the revenue Claris Lifesciences, the Holding Company of
generation was Rs 30 crore during the FY18-19. Claris Injectables Limited, has been continuously
The company showed a growth of 7 per cent with declining since the FY16-17 from Rs 32 crore to Rs 25
respect to the count in the FY17-18 at Rs 28 crore. crore during the FY18-19 in the blood products space.
GSBP is one of the only four companies in the world, This trend gradually picked up when Claris Injectables
pre-qualified by WHO for UNICEF supply of BCG was sold to Baxter International Inc. in July 2017. Claris
Vaccine for immunization against Tuberculosis. Lifesciences was originally incorporated in 1999.
Besides BCG, the company is also developing
vaccines against measles, mumps, rubella, rabies and
tetanus.

43WALLACE ALKEM 44
LABORATORIES
PHARMACEUTICALS LTD
PVT LTD
The revenue count in the FY18-19 for Mumbai
Goa based Wallace Pharmaceuticals Pvt based Alkem Laboratories was at Rs 23 crore
Ltd generated a revenue of Rs 24 crore in in the biologics space, marking a growth
the biologics space, exhibiting a growth of 13 per cent when compared to the revenue
of 17 per cent as compared to Rs 20 crore worth generated during the FY17-18 at Rs 21 crore. With a
revenue generated in the FY17-18. The company comprehensive portfolio of over 750 brands covering
markets a basket of over 200 products focusing major therapeutic segments such as dermatology,
on Antibiotics, Gastro-intestinal, Rheumatology, diabetology, oncology, cardiology, anti-infective, the
Dermatology, Gynecology, Diabetology, ENT and company has a total of 21 manufacturing facilities
Pediatrics. Wallace Pharma is a part of the Wallace including 19 in India and 2 the United States.
Group which also handles Indi Pharma and Goodwin
Biotechnology Inc.

42 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

RPG LIFE 44 JUGGAT 44
SCIENCES LTD PHARMA LTD

Mumbai based RPG Life Sciences recorded During the FY18-19, Mysuru based Juggat
a revenue generation of Rs 23 crore in the Pharma generated a revenue count of Rs 23
biologics space in the FY18-19, showing a crore in the biologics space, growing by 6 per
growth of 70 per cent when compared to the revenue cent in comparison to the revenue generated in the
generated during the FY17-18 at Rs 13 crore. With FY17-18 at Rs 21 crore. A part of Jagdale Industries,
manufacturing facilities located in Ankleshwar, Gujarat Juggat Pharma manufactures Tablets, Liquid Orals,
and Navi Mumbai, Maharashtra, the company is Capsules, Granules and Small Volume Parenterals.
primarily focused on Pharmaceuticals, Fermentation With around 40 products in its portfolio, the company
and Biotechnology. RPG Life Sciences, a part of has distribution network spans all over India.
RPG Enterprises, is operating in the domestic and
international markets in the Branded Formulations,
Global Generics and Synthetic APIs space.

45ASTRAZENECA 45CADILA

PHARMA INDIA PHARMACEUTICALS
LIMITED LTD

For Bengaluru based Astra Zeneca Pharma India, Ahmedabad based Cadila Pharmaceuticals
the revenue generation was Rs 21 crore during generated a revenue of Rs 21 crore in the
the FY18-19 in the biologics space. The company biologics space, exhibiting a growth of 44
showed a growth of 27 per cent with respect to the per cent as compared to Rs 14 crore worth revenue
count in the FY17-18 at Rs 16 crore. With a workforce generated in the FY17-18. The company’s focus
of over 1500 employees across the country, the therapy areas include gastroenterology, cardiology,
company has an innovative portfolio in crucial areas cardiovascular, gynaecology and diabetology. The
of healthcare including cardiovascular, diabetes, manufacturing facilities at Cadila Pharma are
oncology and respiratory. approved by stringent International bodies like WHO-
GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-
Italy.

46JAGSONPAL CORONA 46
REMEDIES
PHARMACEUTICALS PVT LTD
LTD
The revenue count in the FY18-19 for Ahmedabad
New Delhi based Jagsonpal Pharmaceuticals based Corona Remedies was at Rs 20 crore in
recorded a revenue generation of Rs 20 crore the biologics space, marking a growth of 36
in the biologics space in the FY18-19, showing a per cent when compared to the revenue generated
growth of 27 per cent when compared to the revenue during the FY17-18 at Rs 15 crore. For Corona, cardio
generated during the FY17-18 at Rs 16 crore. Founded metabolic and neutraceuticals segments are the
in 1964, the company specializes in developing and focus areas, while it has a significant presence in the
manufacturing bulk drugs and pharmaceutical gynecology, infertility and neuropathy segments. In
formulations. Besides India, the company’s operations 2018, it acquired two brands in the prescription drug
span Russia, Brazil, USA, Ukraine, Sri Lanka, Cameroon, category from Abbott India Ltd for managing diabetes
Thailand, Argentina, Germany, Switzerland, Korea, and hyperthyroidism.
Egypt and Vietnam.

The Total Agilent Experience - 2019 Learn more and register today at
https://explore.agilent.com/TAE-India
Mumbai, 17 June and Hyderabad, 21 June
Scan the code below:
Join us for these featured events:

– Pharma Regulatory Summit : Share and gain knowledge on the
regulatory landscape. Broaden your horizon on data usefulness and
integrity through interactive workshops.

– Biopharma Summit : Gain a greater understanding of key challenges,
trends, and regulations for various analytical solution.

– Analytical Summit for Applied Markets : Find out about the latest
approaches to food authenticity testing and impurity analysis.

Seating is limited. Don’t miss this excellent opportunity to learn and
network with your peers.

© Agilent Technologies, Inc. 2019

44 COVER STORY BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

47FERRING BOEHRINGER 48
INGELHEIM
PHARMACEUTICALS INDIA PVT LTD
PVT LTD
Mumbai based Boehringer Ingelheim India
The Indian subsidiary of Swiss multinational recorded a revenue generation of Rs 18
company Ferring Pharmaceuticals generated crore in the biologics space in the FY18-19,
a revenue figure of Rs 19 crore in the biologics showing a decline of 31 per cent when compared to
space during FY18-19, growing at 16 per cent in the revenue generated during the FY17-18 at Rs 26
comparison to Rs 17 crore generated in FY17-18. crore. Boehringer Ingelheim India operates through
Ferring deals with reproductive medicine and its business areas of Human Pharmaceuticals,
women’s health with strong presence in areas within Animal Health and Clinical operations. The company
gastroenterology and urology. In July 2018, Ferring has entered into a strategic alliance with Lupin for
announced the opening of a manufacturing facility diabetes treatment in India.
and R&D centre in Hyderabad following with an
investment of $250 million.

48NEON MERCURY 49
HEALTHCARE
LABORATORIES PVT LTD
LTD
Mumbai based Mercury Healthcare recorded
The revenue count in the FY18-19 for Mumbai a revenue generation of Rs 17 crore in the
based Neon Laboratories was at Rs 18 crore in the biologics space in the FY18-19, showing a
biologics space, marking a growth of 8 per cent growth of 11 per cent when compared to the revenue
when compared to the revenue generated during the generated during the FY17-18 at Rs 15 crore. The
FY17-18 at Rs 17 crore. Since 1982, the company has company manufactures stable and therapeutically
been constantly expanding its business by developing, effective formulations in independent manufacturing
licensing, manufacturing and marketing. The group is facilities across India.
presently having 3 manufacturing facilities confirming
to Good Manufacturing Practice as prescribed by
World Health Organization.

OAKNET 50 RAPTAKOS, 50
HEALTHCARE BRETT & CO. LTD
PVT LTD

For Bengaluru based Oaknet Healthcare, the The revenue generated in the FY18-19 for
revenue generation was Rs 16 crore during the Mumbai based Raptakos, Brett & Co. was at
FY18-19 in the biologics space, going steady when Rs 16 crore in the biologics space, marking
compared to the same amount generated during the a growth of 10 per cent when compared to the
FY17-18. With heritage brands like Cosvate & Flucos in revenue generated during the FY17-18 at Rs 15 crore.
Dermatology and Jectocos & Ferose in Gynaecology, The company specializes in pharmaceuticals and
the major focus therapy areas for the company are nutraceuticals. The company’s pharmaceutical
Cardiology, Diabetology, Orthopedics. Oaknet is an products cover several therapeutic area such as
entrepreneurial venture set up in 2015 by former Lupin Haematinics, gastrointestinals, digestive enzymes, to
executive RS Raghav. name a few.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com PEOPLE NEWS 45

Cipla brings First Indian woman
Dr Raju Mistry on board scientist gets elected as FRS

Cipla announces the appointment of Dr Raju Mistry Adding to her long list of accomplishments,
as President and Global Chief People Officer (GCPO) Prof. Gagandeep Kang, Executive Director,
of Cipla. Dr Raju is an accomplished and veteran Translational Health Science and Technology
Human Resources (HR) leader with over 27 years of Institute (THSTI), has been elected as a Fellow of
global experience The Royal Society (FRS) for 2019. The election to
across diverse the prestigious society is especially important as
sectors such this makes Prof. Kang the first woman working
as Chemicals, in India to be elected to the Society in the 400+
Pharma, FMCG, years of its history. She has been awarded the
IT, Engineering fellowship in recognition of her contributions to
and Textiles. Prior vaccine development in India and establishment
to joining Cipla, of training programs in clinical translational
she was Chief medicine.
Human Resources
Officer (CHRO)
at Jubilant Life
Sciences Ltd. For 13 years before that, Dr Raju led the
talent, employer brand and leadership programmes
of the Aditya Birla Group, and was CHRO of Grasim’s
Pulp and Fibre business. She has previously worked
with Tata Sons, Colgate Palmolive, Siemens, and
Mastech Corporation, Canada.

46 PEOPLE NEWS BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

Dr Yasir Rawjee joins Novartis picks Sanjay
as CEO at Glenmark Murdeshwar to lead India biz
Life Sciences
Swiss drug company Novartis has appointed the
Glenmark Pharmaceuticals Ltd has current Global Vice President, Cardio-Renal business at
announced that it has appointed Dr AstraZeneca, Sanjay Murdeshwar, to lead its business in
Yasir Rawjee as the Chief Executive India. Murdeshwar has earlier also been the India head of
Officer of Glenmark Life Sciences AstraZeneca for the period of 2013-2017.
Ltd, its subsidiary for the API (Active
Pharmaceuticals Ingredients)
business. Yasir joins Glenmark Life
Sciences from Mylan Inc where most
recently, he was the Head of Global
API Operations. He has held positions
of increasing responsibility at Mylan
including Senior Vice President of
API Technical Operations and Senior
Vice President and Head for Sales and
Marketing for the API Business.

Lupin ropes in Takeda announces
ex-Cipla executive Andrey Potapov as
ICMEA Area Head
Lupin Pharmaceuticals has named
ex-Cipla executive Preeti Bose as the Global biopharmaceutical company Takeda has announced
global head of talent management Andrey Potapov as its Area Head for India, CIS (the
and leadership development. Prior Commonwealth of Independent States), the Middle East
to this, Preeti was working in including Turkey, and Africa (ICMEA). In his most recent
another pharma company Cipla, as role as General Manager of Takeda Russia and Head of the
the global head of their leadership CIS Area, Potapov oversaw the successful launch of new
academy. At Cipla, Preeti provided pharmaceutical products, while delivering above market
strategic thought leadership for the profit growth for the past five years.
development of approximately 24,000
global associates; specifically - talent
development of top 200 leaders,
managerial capability building
across the spectrum for new and
senior people managers, along with
designing and delivering programmes
for transformational business needs
and behavioural skills in line with
Cipla Leadership Essentials.

BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com SUPPLIER NEWS 47

Beckman Coulter Agilent to supply
unveils total laboratory custom microarrays
automation solution
Agilent Technologies and SomaLogic have
Beckman Coulter, a global leader in clinical announced a multi-year supply agreement
diagnostics, announced that the latest addition to whereby Agilent will supply customized high-
its market-leading automation portfolio, the DxA fidelity oligo microarrays for use in the nucleic
5000 total laboratory automation solution has acid detection step within SomaLogic’s novel
achieved European CE Mark and China Food and SOMAscan assay, a protein measurement
Drug Administration approval. The DxA 5000 sets a platform with applications across basic
new standard by utilizing a universal centrifugation and clinical research, diagnostics, and
protocol that significantly reduces the pre-analytical pharmaceutical discovery and development.
processing time by up to 73 per cent for connected
analyzers across multiple disciplines.

48 SUPPLIER NEWS BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

IKA launches new all-rounder in coarse and fine crushing

Grinding, mixing, dispersing, tasks. IKA laboratory technology equipment for numerous
weighing and temperature offers a wide range of innovative applications in research and
measurement in a single
laboratory instrument: The new development. The new
IKA MultiDrive is the first true crusher from IKA is
all-rounder in the area of coarse suitable for applications
and fine crushing. This world in pharmacy, medicine,
first is available from IKA now, the food industry,
for a wide variety of grinding biology or the biomass
sector.

BD introduces Rockwell Automation releases
PRIME in AI module to improve
conjunction with industrial production
JCI in India
Rockwell Automation is releasing an AI Module in India that
BD (Becton, Dickinson and would ease decision-making for manufacturers by providing
Company), a leading global medical predictive analytics. They continue to provide automation
technology company, has launched solutions to Indian manufacturers across sectors like
a new patient safety programme for pharma & life sciences, FMCG, packaging, and many more.
hospitals, called Preventing Risks The new FactoryTalk Analytics LogixAI module, formerly
of Infections and Medication Errors known as Project Sherlock, uses artificial intelligence (AI) to
in IV Therapy (PRIME). Aimed at detect production anomalies and alert workers so they can
addressing the two critical challenges investigate or intervene, as necessary.
in a hospital setting - infection
prevention and medication safety Thermo Fisher to develop
– PRIME is developed by Joint pregnancy outcome assay
Commission International for Patient
Safety, with sponsorship by BD. Thermo Fisher Scientific, the world leader in serving science, and
A unique programmematic approach NX Prenatal Inc., a recognized leader in the detection, monitoring
towards patient safety will be and management of pregnancy-related complications using
implemented over a six-month novel exosome-based methods, have entered into a collaboration
duration, composed of goal- to develop clinical mass spectrometry-based proteomics assays
setting, constant progress review, to monitor fetal health in utero and assess the risk of adverse
tele-consultations with experts outcomes, including preterm birth and preeclampsia. This
and scientific updates through new collaboration recognizes the challenges faced by medical
webinars. Hospitals will be certified professionals who have few tools available for noninvasive risk
upon successful completion of the stratification for adverse pregnancy outcomes.
programme.



50 BIO EVENT BIOSPECTRUM | JUNE 2019 | www.biospectrumindia.com

“India is expected to meet the WHO
norm of 1:1000 doctor-patient ratio by 2024”
Dr V K Paul, Member
(Health), NITI Aayog said Dr VK Paul, Member (Health), NITI Aayog speaking at a session on “specialist training
that in next 5 years, India to tackle the burden of NCDs” organized by FICCI India on May 3 in New Delhi.
will have 2,500 new hospitals
thereby creating 2.5 million attaining the required number of empowering GPs on diabetes
additional jobs. By 2024, India specialist doctors is a five times management can vastly improve
is also likely to attain the WHO more difficult agenda. He further patient outcomes as about 95%
norm of having one doctor for added that 80,000 PG seats will be of the diabetics in India are
every thousand patients, he said. added by 2024, with participation being attended to by primary
of private sector healthcare care doctors, GPs and family
Speaking at the launch of providers. physicians.
certificate course on ‘Specialist
Training To Tackle The Burden Manoj Jhalani, AS & MD Sharing ECHO’s vision of
of Noncommunicable diseases (NHM), Ministry of Health and touching 1 billion lives by 2025,
(NCDs)’ organized by Federation Family Welfare, Government of Dr Sanjeev Arora, Founder &
of Indian Chambers of Commerce India highlighted the quadruple Director, Project ECHO said, “Out
and Industry (FICCI) Dr Paul challenge of quantity, quality, right of the 1 billion, we want to reach
added that with the improvement skill-mix and physical distribution 400 million beneficiaries in India,
in the ease of doing business in of human resources for healthcare. through training doctors using
the private healthcare sector, He said, “It is important to the ECHO model of integrated
new players will enter the sector empower primary health teams guided practice. India needs to
which will not only create new and General Physicians (GPs). exponentially increase its capacity
employment opportunities but also The Ministry is working on several building programs and this is
provide better healthcare services. aspects to increase number of not possible without leveraging
specialist doctors in the country technology.” He said that through
FICCI, jointly with NITI Aayog, and is also exploring participatory these partnerships about 1,000
has been working on identifying approaches for engaging private training hubs can be set up in
innovative alternate methods sector like contribution for India. This can be a game changer
of strengthening the number of stipends paid to DNB students at and once proven successful, can
specialized doctors in India that both public and private hospitals.” be replicated to other disease
can be scaled-up, especially for high conditions or specialties or to other
burden diseases and conditions. Appreciating the government’s sectors like primary education, he
In continuation to this, FICCI has focus on health, (Hony) Brig Dr added.
partnered with ECHO (Extension Arvind Lal, Chairman, FICCI
for Community Healthcare Health Services Committee & The FICCI-ECHO Diabetes
Outcomes) to launch the first of its CMD, Dr Lal Path Labs said, “We Certification Course for GPs is a
kind Diabetes Certification Course all quote the British, US, Cuban, 20-week, tele-mentoring program
for General Practitioners (GP), Thai and Indonesian models of that will be initially taken up as a
considering the WHO statistics healthcare, but with Ayushman pilot project to train 100 GPs on
of 69.2 million Indians suffering Bharat, an Indian model will logical management of diabetic
with diabetes in 2015 and not emerge.” He further added that patients.
enough endocrinologists to deliver
specialized care.

Commenting on the tie-up, Dr
V K Paul said, “The ECHO model
is unique in more than one ways,
but what makes this program even
more unique is the partnership
with the industry through FICCI”.
He also highlighted that the
government has made provisions
to double the number of UG seats
in medical education by 2024, but